<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine: The Massachusetts General Hospital Handbook of Internal Medicine</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../k34gmbu8.html">Pocket Medicine
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0010.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0012.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h82" class="calibre7"></a><a id="page_6-1" class="calibre7"></a><a href="part0002.html#rh91" class="calibre7">PNEUMONIA</a></h2>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Microbiology of Pneumonia</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Clinical Setting</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Etiologies</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Community- acquired (CAP)</b> <span class="tfont">(</span><span class="tfont"><i class="calibre3">NEJM</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">4;37</span><span class="tfont">1</span><span class="tfont">:</span><span class="tfont">1</span><span class="tfont">6</span><span class="tfont">1</span><span class="tfont">9 &amp; 373:4</span><span class="tfont">1</span><span class="tfont">5;</span> <span class="tfont"><i class="calibre3">Lancet</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">5;386:</span><span class="tfont">1</span><span class="tfont">097)</span></p></td>
<td class="bg0-b"><p class="tabh"><i class="calibre3">No pathogen identified in 50–60%</i>, virus alone in ~25%, bacteria alone in ~10%, virus-bacteria coinfection in &lt;5%</p>
<p class="tabh">Viruses: influenza, RSV, hMPV, rhinovirus (unknown significance), parainfluenza virus, coronavirus</p>
<p class="tab"><i class="calibre3">S. pneumoniae</i> (most common bacterial cause)</p>
<p class="tab"><i class="calibre3">S. aureus</i> (esp. postinfluenza)</p>
<p class="tab"><i class="calibre3">Mycoplasma</i>, <i class="calibre3">Chlamydia</i> (esp. in young &amp; healthy)</p>
<p class="tab"><i class="calibre3">H. influenzae</i>, <i class="calibre3">M. catarrhalis</i> (esp. in COPD)</p>
<p class="tab"><i class="calibre3">Legionella</i> (esp. in elderly, smokers, ↓ immunity, TNF inhibitors)</p>
<p class="tab"><i class="calibre3">Klebsiella</i> &amp; other GNR (esp. in alcoholics &amp; aspiration)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Hospital-acquired or ventilator-assoc. (HAP/VAP)</b></p></td>
<td class="bg0-b"><p class="tabh"><i class="calibre3">S. aureus</i>, <i class="calibre3">Pseudo.</i>, <i class="calibre3">Klebsiella</i>, <i class="calibre3">E. coli, Enterobacter</i>, <i class="calibre3">Acinetobacter, Stenotrophomonas.</i> IV abx w/in 90 d RF for MDR.</p>
<p class="tab">Viral~ 20% cases <span class="tfont">(</span><span class="tfont"><i class="calibre3">Chest</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">7;</span> <span class="tfont">1</span><span class="tfont">54:</span><span class="tfont">1</span><span class="tfont">)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Immunosuppressed</b></p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Above</i> + PCP, fungi, <i class="calibre3">Nocardia</i>, non-TB mycobacteria (NTM), CMV</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Aspiration</b> <span class="tfont">(</span><span class="tfont"><i class="calibre3">NEJM</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">9;380:65</span><span class="tfont">1</span><span class="tfont">)</span></p></td>
<td class="bg"><p class="tab"><i class="calibre3">Chemical pneumonitis</i> due to aspiration of gastric contents</p>
<p class="tabh"><i class="calibre3">Bacterial pneumonia</i> ≥24–72 h after aspiration event outPt: oral flora (strep, <i class="calibre3">S. aureus</i>, anaerobes) inPt or chronically ill: GNR (<i class="calibre3">Pseudomonas</i>) and <i class="calibre3">S. aureus</i></p></td>
</tr>
</table>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Presenting features are variable and depend upon several host factors (esp. age)</p>
<p class="bl"><span class="sbl">•</span> Classically: fever, cough w/ purulent sputum, consolidation on CXR</p>
<p class="bl"><span class="sbl">•</span> Atypical pathogens (<i class="calibre3">Legionella, Mycoplasma, Chlamydia</i>, virus): historically classified as “atypical” b/c they failed to grow on routine cx. Presentation varies from insidious to acute; imaging features vary from interstitial infiltrates to tree-in-bud opacities, to dense consolid.</p>
<p class="bl"><span class="sbl">•</span> Clinical and imaging features do NOT distinguish “typical” from “atypical”</p>
<p class="bl"><span class="sbl">•</span> Aspiration pneumonitis/PNA: can be infectious or non-infectious; may p/w acute inflammatory syndrome (fever, ↑ WBC, etc.) or insidious course</p>
<p class="bl"><span class="sbl">•</span> HAP/VAP: develops w/in 48 h after admission or mechanical ventilation, respectively</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Sputum Gram stain/Cx:</b> reliable if high quality (ie, sputum not spit; &lt;10 squamous cells/lpf) &amp; if PNA should be purulent (&gt;25 PMNs/lpf). Yield ↓ &gt;10 h after abx <span class="s1r">(<i class="calibre3">CID</i> 2014;58:1782)</span>.</p>
<p class="bl"><span class="sbl">•</span> Blood cultures (<i class="calibre3">before antibiotics!</i>): ⊕ in ~10% of inPts, depending on pathogen</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Procalcitonin:</b> ↑ in acute bacterial (not viral) PNA. Consider stopping abx if levels &lt;0.25 ng/ml (&lt;0.5 ng/ml in ICU Pts) or ↓ ≥80% from peak. ↓ abx exposure by 2–3 d <span class="s1r">(<i class="calibre3">Lancet ID</i> 2016;16:819 &amp; 2018;18:95)</span>. Not validated in immunocompromised hosts. Levels harder to interpret in CKD. False ⊕ in cardiac arrest, shock, surgery.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CXR</b> (PA &amp; lateral; see Radiology inserts) → tap effusions if &gt;5 cm or severe PNA</p>
<p class="bl"><span class="sbl">•</span> Other: <b class="calibre4">S<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub></b> or P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub>, arterial pH (if severe), CBC w/ diff, Chem-20; HIV test (if unknown)</p>
<p class="bl"><span class="sbl">•</span> Other micro based on clinical suspicion (paired serologies available for most atypicals):</p>
<p class="bl1"><i class="calibre3">Mycoplasma:</i> PCR of throat or sputum/BAL <i class="calibre3">before</i> first dose abx</p>
<p class="bl1"><i class="calibre3">Legionella</i> urinary Ag (detects <i class="calibre3">L. pneumophila</i> L1 serotype, 60–70% of clinical disease)</p>
<p class="bl1"><i class="calibre3">S. pneumoniae</i> urinary Ag (Se 70%, Sp &gt;90%)</p>
<p class="bl1">MTb: (induced) sputum AFB stain ×3 q ≥8h (w/ ≥1 early morning specimen). Myco-bacterial cx (<i class="calibre3">empiric respiratory isolation while pending</i>); MTb DNA PCR if smear ⊕.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Viral testing</b> (DFA or PCR) on nasopharyngeal swab or sputum</p>
<p class="bl"><span class="sbl">•</span> Bronchoscopy: consider if immunosupp., critically ill, failing to respond, VAP, suspected TB or PCP, or inadequate or ⊖ sputum cx. Some pathogens need specific cx media (eg, <i class="calibre3">Legionella</i> on BCYE).</p>
<p class="bl"><span class="sbl">•</span> Reasons for failure to improve on initial Rx:</p>
<p class="bl1">Insufficient time: may take ≥72 h to see improvement (fever persists &gt;4 d in ~20%)</p>
<p class="bl1">Insufficient drug levels for lung penetration (eg, vanco trough &lt;15–20 μg/mL)</p>
<p class="bl1">Resistant organisms (or superinfxn): eg, MRSA, <i class="calibre3">Pseudo.;</i> consider <b class="calibre4">bronchoscopy</b></p>
<p class="bl1">Wrong dx: fungal/viral, chemical pneumonitis, PE, CHF, ARDS, DAH, ILD; <b class="calibre4">consider CT</b></p>
<p class="bl1">Parapneumonic effusion/empyema/abscess: if CXR ⊖, <b class="calibre4">consider CT</b> (dx tap ± chest tube if effusion present, esp. if loculated)</p>
<p class="bl1">Metastatic infection (eg, endocarditis, meningitis, septic arthritis)</p>
<p class="h2a">Triage</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">qSOFA</b> predicts poor outcomes, prolonged ICU stay, and in-hospital mortality if &gt;2 of 3: RR&gt;22, AMS, SBP&lt;100 <span class="s1r">(<i class="calibre3">JAMA</i> 2016; 315:801)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CURB-65:</b> confusion, BUN &gt;20, RR &gt;30, BP &lt;90/60, age &gt;65 If score 0–1: Rx as outpt; 2: Rx as inpt; &gt;3 consider ICU <span class="s1r">(<i class="calibre3">Thorax</i> 2013; 58:377)</span></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre38"/>
<col class="calibre48"/>
<col class="calibre63"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><a id="page_6-2" class="calibre1"></a><p class="tabheadc"><b class="calibre4">Treatment</b> <span class="tfont">(</span><span class="tfont"><i class="calibre3">CID</i></span> <span class="tfont">2007;44 Suppl:S27;</span> <span class="tfont"><i class="calibre3">JAMA</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">6;3</span><span class="tfont">1</span><span class="tfont">5:593;</span> <span class="tfont"><i class="calibre3">NEJM</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">9;380:65</span><span class="tfont">1</span><span class="tfont">)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Scenario</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Regimen</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Special Considerations</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">CAP (outPt)</b></p></td>
<td class="bg0-br"><p class="tab">Azithro <i class="calibre3">or</i> doxy</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Avoid</i> azithro/doxycycline if &gt;25% resist- ance locally. Use FQ OR B-lactam + azithro/doxy.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">CAP (ward)</b></p></td>
<td class="bg0-br"><p class="tab">Resp FQ <i class="calibre3">or</i> [3<sup class="calibre35">rd</sup>-gen ceph + azithro]</p></td>
<td class="bg0-b"><p class="tab">Doxycycline can replace azithro</p>
<p class="tab"><b class="calibre4">Omadacycline</b> ≈ FQ <span class="tfont">(</span><span class="tfont"><i class="calibre3">NEJM</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">9;380:5</span><span class="tfont">1</span><span class="tfont">7)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">CAP (ICU)</b></p></td>
<td class="bg0-br"><p class="tab">Resp FQ + [3<sup class="calibre35">rd</sup>-gen ceph <i class="calibre3">or</i> amp-sulbactam]</p></td>
<td class="bg0-b"><p class="tab">Only cover MRSA or Pseudomonas if risk factors. If resp FQ contraindic., use azithro</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">HCAP (incl. VAP)</b></p></td>
<td class="bg0-br"><p class="tab">[Pip-tazo <i class="calibre3">or</i> cefepime <i class="calibre3">or</i> carbapen.] + [vanco or linezolid]</p></td>
<td class="bg0-b"><p class="tab">May add resp FQ (or azithro) when concerned re: atypicals</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Aspiration</b></p></td>
<td class="bg" colspan="2"><p class="tab">Treat if abnl CXR (or if need to be intubated or develops septic shock)</p>
<p class="tab">Amox-clav, amp-sulbactam, FQ, carbapenem</p>
<p class="tabh">If hosp-acquired and concern for multidrug-resistant pathogens: [pip-tazo, cefepime, or carbapenem] + [AG or colistin]</p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> Avoid quinolones if suspect TB</p>
<p class="bl"><span class="sbl">•</span> Steroids: not standard practice, but appear to ↓ mortality, mech vent, &amp; ARDS <span class="s1r">(<i class="calibre3">Cochrane</i> 2017;12:CD007720)</span>. Consider in severe CAP (F<sub class="calibre8">i</sub>O<sub class="calibre8">2</sub> &gt;0.5 + ≥1 of: pH&lt;7.3; lactate &gt;4; CRP &gt;150). <i class="calibre3">Avoid</i> in suspected or known influenza. Dosing: pred 50 mg PO ×7 d or methylpred 0.5 mg/kg IV BID ×5 d.</p>
<p class="bl"><span class="sbl">•</span> Duration: for CAP, 5 d if stable &amp; afebrile for 48–72 h; for HAP/VAP, 8 d <span class="s1r">(<i class="calibre3">CID</i> 2017; 65:8)</span></p>
<p class="bl"><span class="sbl">•</span> When possible, de-escalate abx based on sensitivities</p>
<p class="h2a">Prognosis</p>
<p class="bl"><span class="sbl">•</span> For low-risk Pts, can discharge immediately after switching to PO abx <span class="s1r">(<i class="calibre3">CID</i> 2007;44:S27)</span></p>
<p class="bl"><span class="sbl">•</span> CXR resolves in most by 6 wk; consider f/u to r/o underlying malig (esp. if &gt;50 y or smoker)</p>
<p class="h2a">Prevention</p>
<p class="bl"><span class="sbl">•</span> All persons &gt;65: give PCV13 vaccine followed by PPSV23 vaccine 1 y later. If PPSV23 already received, give PCV13.</p>
<p class="bl"><span class="sbl">•</span> Age 19–64 w/ CHF/CMP, lung disease (including asthma), cirrhosis, DM, EtOH, or smoker: give PPSV23.</p>
<p class="bl"><span class="sbl">•</span> Any age w/ immunocomp., CSF leak, cochlear implant, asplenia: give PCV13 followed by PPSV23 8 wks later.</p>
<p class="bl"><span class="sbl">•</span> Smoking cessation counseling</p>
<p class="bl"><span class="sbl">•</span> VAP precautions: HOB &gt;30°, chlorhexidine rinse; aspiration precautions in high-risk Pts</p>
<p class="h">V<small class="calibre30">IRAL</small> R<small class="calibre30">ESPIRATORY</small> I<small class="calibre30">NFECTIONS</small></p>
<p class="cst"><i class="calibre3">URI, bronchitis, bronchiolitis, pneumonia</i> <span class="s">(<i class="calibre3">Lancet</i> 2011;377:1264)</span></p>
<p class="h2a">Microbiology &amp; epidemiology <span class="s">(<a href="http://www.cdc.gov/flu/weekly" class="calibre1">http://www.cdc.gov/flu/weekly</a>)</span></p>
<p class="bl"><span class="sbl">•</span> Typical pathogens</p>
<p class="bl1">short, mild = rhinovirus, coronavirus</p>
<p class="bl1">longer, more severe or complicated = <b class="calibre4">influenza</b>, parainfluenza, respiratory syncytial virus (RSV), adenovirus, metapneumovirus. Can be esp. severe in immunosupp.</p>
<p class="h2a">Diagnosis</p>
<p class="bl"><span class="sbl">•</span> Sx: fever, cough, myalgias, SOB, wheezing, sore throat, rhinorrhea, malaise, confusion</p>
<p class="bl"><span class="sbl">•</span> Respiratory viral panel on nasal washing or sputum/BAL</p>
<p class="bl"><span class="sbl">•</span> Rapid influenza <i class="calibre3">nasopharyngeal swab</i> preferred to nasal swab (Se 50–70%, Sp &gt;90%)</p>
<p class="bl"><span class="sbl">•</span> RT-PCR for influenza A/B (&gt;95% Se &amp; Sp)</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">NEJM</i> 2017;390:697)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Influenza:</b> neuraminidase inhib. (oseltamivir, zanamivir), which are effective vs. A &amp; B (↓ sx by ~1 d), but resistance emerging.</p>
<p class="bl"><span class="sbl">•</span> Oseltamivir dosed 75 mg PO bid × 5 d. Must start w/in 48 h of sx for low-risk; for critically ill or immunosupp., start ASAP even if &gt;48 h.</p>
<p class="bl"><span class="sbl">•</span> Baloxavir superior to oseltamivir in ↓ sx &amp; viral load on 1<sup class="calibre15">st</sup> day of Rx, but risk of resistance emerges w/in Pts <span class="s1r">(<i class="calibre3">NEJM</i> 2018; 379:913)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">RSV:</b> Can consider inhaled ribavirin in immunosupp. (eg, BMT, lung tx); limited adult data</p>
<p class="h2a">Prevention</p>
<p class="bl"><span class="sbl">•</span> Inactivated <b class="calibre4">influenza vaccine:</b> incl. H1N1. Rec for <i class="calibre3">all</i> &gt;6 mo of age and esp. if pregnant, &gt;50 y, immunosupp., or HCW <span class="s1r">(<i class="calibre3">MMWR</i> 2012;61:613)</span></p>
<p class="bl"><span class="sbl">•</span> Isolation, droplet precautions for inPts strongly recommended</p>
<p class="bl"><span class="sbl">•</span> Prophylaxis for high-risk contacts of confirmed influenza: oseltamivir 75 mg PO daily × 10 d</p>
<h2 class="ct"><a id="h83" class="calibre7"></a><a id="page_6-3" class="calibre7"></a><a href="part0002.html#rh92" class="calibre7">FUNGAL INFECTIONS</a></h2>
<p class="h2a"><b class="calibre4">Fungal diagnostics</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Antigen detection</b></p>
<p class="bl1"><b class="calibre4">1,3-β-D glucan</b> (Se 77%, Sp 86%): <b class="calibre4">Candida, Aspergillus, Histo, Coccidio, PCP</b>. <i class="calibre3">Cannot</i> detect Mucor, Rhizopus, Blasto, Crypto. False ⊕ w/ IVIG, albumin, HD, gauze.</p>
<p class="bl1"><b class="calibre4">Galactomannan</b> (Se 40%, but <i class="calibre3">improved to 85% w/ BAL</i>; Sp 89%) <b class="calibre4">d</b>etects <b class="calibre4">Aspergillus</b>. Test <i class="calibre3">serum</i> if heme malig or HSCT. Do not use for screening or Rx monitoring in solid organ Tx, chronic granulomatous dis., or Rx/ppx for Asperg. (false ⊕ w/ colonization).</p>
<p class="bl1"><b class="calibre4">Histo urine/serum Ag</b>: Se of urine Ag 90% (serum 80%) if dissem; Sp limited by X-react</p>
<p class="bl1"><b class="calibre4">Crypto Ag</b> (serum, CSF): serum Ag &gt;90% Se &amp; Sp in invasive infxn, less for pulm only</p>
<p class="bl1"><b class="calibre4">Blastomyces:</b> urine &gt; serum Ag, high Se but modest Sp given X-react w/ other fungi</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Culture</b>: <i class="calibre3">Candida</i> grows in blood/urine Cx, but ↓ Se of BCx in deep tissue infection; others (eg, <i class="calibre3">Crypto</i>, <i class="calibre3">Histo</i>) ↓↓ Se of BCx; if suspect <i class="calibre3">Coccidio</i> alert lab <i class="calibre3">(biohazard)</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Antibody detection</b>: only useful for <i class="calibre3">Coccidio</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Biopsy</b> (histopathology): no grinding of tissue if Zygomycetes suspected</p>
<p class="h2a">Candida species</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Microbiology:</b> normal GI flora; <i class="calibre3">C. albicans</i> &amp; nonalbicans spp.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Risk factors:</b> neutropenia, immunosupp., broad-spectrum abx, intravascular catheters (esp. if TPN), IVDU, abd surgery, DM, renal failure, age &gt;65</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Clinical manifestations</b></p>
<p class="bl1">Mucocutaneous: cutaneous (eg, red, macerated lesions in intertriginous zones); oral thrush (exudative, erythematous or atrophic; if unexplained, r/o HIV); esophageal (odynophagia; ± oral thrush); vulvovaginal, balanitis</p>
<p class="bl1"><b class="calibre4">Candiduria:</b> typically <i class="calibre3">colonization</i> due to broad-spectrum abx and/or indwelling catheter</p>
<p class="bl1"><b class="calibre4">Candidemia:</b> <i class="calibre3">never a contaminant!</i> R/o retinal involvement (ophtho consult in all cases as req ↑ Rx duration); endocarditis rare but serious (esp. w/ nonalbicans &amp; prosthetic valve). May present with erythematous papules or pustules in immunocompromised.</p>
<p class="bl1">Hepatosplenic: occurs w/ neutrophil recovery</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre29"/>
<col class="calibre44"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Treatment</b> <span class="tfont">(</span><span class="tfont"><i class="calibre3">CID</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">6;62:409)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Mucocutaneous</p></td>
<td class="bg0-b"><p class="tab">Clotrimazole, nystatin, fluconazole, itraconazole</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Candiduria <i class="calibre3">(if pyuria or sx of infxn)</i></p></td>
<td class="bg0-b"><p class="tab">Fluconazole or intravesical ampho if sx, severely</p>
<p class="tab">immunosupp. or will undergo GU procedure</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Candidemia w/o neutropenia</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Echinocandin</b> (mica 1<sup class="calibre35">st</sup> line) <i class="calibre3">or</i> fluc <i class="calibre3">or</i> ampho; <i class="calibre3">remove intravascular catheters if possible</i>. <i class="calibre3">Test for azole resist</i>.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Febrile neutropenia</p></td>
<td class="bg"><p class="tab"><b class="calibre4">Echinocandin</b> <i class="calibre3">or</i> ampho</p></td>
</tr>
</table>
<p class="h2a">Cryptococcus <span class="s">(<i class="calibre3">CID</i> 2010;50:291)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Epidemiology:</b> immunosupp. (esp. AIDS) most susceptible; can occur in healthy host, esp. elderly, EtOH, DM. Consider <i class="calibre3">C. gattii</i> (typically in healthy host).</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Clinical manifestations</b></p>
<p class="bl1"><b class="calibre4">CNS</b> (meningitis): HA, fever, meningismus, ↑ ICP, CN abnl, ± stupor, often subacute. Dx: CSF CrAg, India ink stain, fungal cx. Cell counts vary; serum CrAg &gt;1:8 Se/Sp in AIDS.</p>
<p class="bl1">Other sites: pulm, GU, cutaneous, CNS cryptococcoma. <i class="calibre3">With any crypto dx, LP all Pts.</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Treatment</b></p>
<p class="bl1">CNS: if ↑ ICP, repeat large-volume LPs or temp. lumbar drain; few require VP shunt</p>
<p class="bl1">CNS Rx has induction (ampho ± flucytosine x2 wks), consolidation and maintenance (fluconazole) phases <span class="s1r">(<i class="calibre3">NEJM</i> 2013;368:1291)</span>. If r/o CNS disease, then fluconazole. Dosing and duration vary by host.</p>
<p class="bl1">Non-CNS disease (pulm, skin, bone, blood) in HIV ⊖ Pts: consider fluconazole</p>
<p class="h2a">Histoplasmosis <span class="s">(<i class="calibre3">CID</i> 2007;45:807)</span></p>
<p class="bl"><span class="sbl">•</span> Endemic to central &amp; SE US, but sporadic cases throughout U.S.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Clinical manifestations</b></p>
<p class="bl1">Acute: often subclinical, but may see mild to severe PNA ± cavitary &amp; hilar LAN</p>
<p class="bl1">Chronic pulm: ↑ productive cough, wt loss, night sweats, apical infiltrates, cavitation</p>
<p class="bl1">Disseminated (typically in immunosupp.): fever, wt loss, HSM, LAN, oral ulcers, skin lesion, fibrosing mediastinitis, reactive arthritis, pericarditis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Treatment:</b> itraconazole (monitor levels); ampho ± steroids if severe or immunosupp</p>
<p class="h2a">Coccidioidomycosis <span class="s">(<i class="calibre3">CID</i> 2016;63:112)</span></p>
<p class="bl"><span class="sbl">•</span> Endemic to SW U.S. (San Joaquin or “Valley” fever)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Clinical manifestations</b></p>
<p class="bl1">Acute: 50–67% subclinical; PNA w/ cough, chest pain, fever, arthralgias, <i class="calibre3">fatigue</i></p>
<p class="bl1">Chronic pulm: nodule(s), cavity or progressive fibrocavitary PNA (can be asx or sx)</p>
<p class="bl1">Disseminated (typically in immunosupp.): fever, malaise, diffuse pulmonary process, bone, skin, &amp; meningeal involvement</p>
<p class="bl"><a id="page_6-4" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">Treatment:</b> monitor mild disease closely q3–6mo; for severe disease: fluconazole, itraconazole or amphotericin</p>
<p class="h2a">Blastomycosis <span class="s">(<i class="calibre3">CID</i> 2008;46:1801)</span></p>
<p class="bl"><span class="sbl">•</span> Endemic to south central, SE, and Midwest U.S.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Clinical manifestations</b></p>
<p class="bl1">Acute: 50% subclinical; cough, multilobar PNA; can progress to ARDS</p>
<p class="bl1">Chronic pulm: cough, wt loss, malaise, CT w/ masses &amp; fibronodular infiltrates</p>
<p class="bl1">Disseminated: (25–40% of all but ↑ in immunosupp.): verrucous &amp; ulcerated skin lesions, bone, &amp; GU involvement; CNS rare unless immunosupp.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Treatment:</b> itraconazole (monitor levels); ampho if severe, disseminated or immunosupp.</p>
<p class="h2a">Aspergillosis <span class="s">(<i class="calibre3">CID</i> 2008;46:327; <i class="calibre3">NEJM</i> 2009;360:1870)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">ABPA; hypersensitivity pneumonitis</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Aspergilloma:</b> usually in pre-existing cavity (from TB, etc.); most asx, but can lead to hemoptysis; sputum cx ⊕ in &lt;50%; CT → mobile intracavitary mass with air crescent</p>
<p class="bl1">Rx: antifungals w/o benefit; embolization or surgery for persistent hemoptysis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Necrotizing tracheitis:</b> white necrotic pseudomembranes in Pts w/ AIDS or lung Tx</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Chronic necrotizing:</b> mild immunosupp.; sputum production, fever, wt loss; CT: infiltrate ± nodule ± thick pleura; lung bx → invasion</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Invasive:</b> seen if immunosupp. (neutropenia for &gt;10 d, transplant, high-dose corticosteroids, AIDS); s/s PNA w/ <i class="calibre3">chest pain</i> &amp; <i class="calibre3">hemoptysis;</i> CT: nodules, halo sign (cavitates w/ Rx → air crescent sign); dx w/ galactomannan &gt;0.5 (serum or BAL)</p>
<p class="bl"><span class="sbl">•</span> Rx (necrotizing/invasive): voriconazole (or isavuconazole) superior to ampho; ✔ drug levels</p>
<p class="h2a">Zygomycetes <span class="s">(eg, <i class="calibre3">Mucor, Rhizopus</i>)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Epidemiology: diabetes</b> (70%, esp. DKA), heme malignancy, s/p transplant, chronic steroids, deferoxamine or iron overload, trauma, h/o voriconazole Rx or Ppx</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Clinical: rhinocerebral</b> = periorbital/forehead pain (more extensive than orbital cellulitis), ± fever (may appear nontoxic at first), exophthalmos, ↓ EOM, CNs (V &gt; VII); nasal turbinates ± black eschar but exam can be quite nl. Also, <b class="calibre4">pulm</b> (PNA w/ infarct &amp; necrosis); <b class="calibre4">cutaneous</b> (indurated painful cellulitis ± eschar); <b class="calibre4">GI</b> (necrotic ulcers).</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Treatment:</b> debridement + Rx (ampho, posaconazole, or isavuconazole); high mortality</p>
<h2 class="ct"><a id="h84" class="calibre7"></a><a href="part0002.html#rh93" class="calibre7">INFXNS IN IMMUNOSUPPRESSED HOSTS</a></h2>
<p class="h2a">Overview</p>
<p class="bl"><span class="sbl">•</span> Many Pts have ≥1 risk (eg, DM, ESRD, transplant, extremes of age)</p>
<p class="bl"><span class="sbl">•</span> The following is not an exhaustive list, but a delineation of common or classic etiologies</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tab"><b class="calibre4">Predisposition</b></p></td>
<td class="bg1-b"><p class="tab"><b class="calibre4">Classic Infectious Etiologies</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Humoral immune dysfunction</b> (eg, CVID, myeloma) and <b class="calibre4">asplenia</b></p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">Encapsulated bacteria:</b> <i class="calibre3">S. pneumo</i>, <i class="calibre3">H. flu</i>, <i class="calibre3">N. meningitidis</i> (vaccinate against these 3, ideally prior to splenectomy)</p>
<p class="tab"><b class="calibre4">Other bacteria:</b> <i class="calibre3">E. coli</i> and other GNRs, <i class="calibre3">Capnocytophaga</i></p>
<p class="tab"><b class="calibre4">Parasites:</b> <i class="calibre3">Babesia, Giardia;</i> <b class="calibre4">Viruses:</b> VZV, echovirus, enterovirus</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Granulocytopenia or neutropenia</b> (includes DM, ESRD → functional impairment)</p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">Bacteria:</b> <span class="underline">Gram positive</span>: coag ⊖ staph, <i class="calibre3">S. aureus</i>, viridans strep, <i class="calibre3">S. pneumo</i>, other strep; <i class="calibre3">Corynebacterium</i> spp., <i class="calibre3">Bacillus</i> spp. <span class="underline">Gram negative</span>: <i class="calibre3">E. coli</i>, <i class="calibre3">Klebsiella</i>, <i class="calibre3">Pseudomonas</i></p>
<p class="tabh"><b class="calibre4">Fungi:</b> <span class="underline">Yeast</span>: <i class="calibre3">Candida albicans</i> and other <i class="calibre3">Candida</i> spp. <span class="underline">Molds</span>: <i class="calibre3">Aspergillus, Mucor</i> spp., endemic fungi and others</p>
<p class="tab"><b class="calibre4">Viruses:</b> VZV, HSV1 and 2, CMV</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Impaired cell-mediated immunity (CMI)</b> (eg, HIV, chronic steroids, posttransplant, DM, ESRD)</p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">Bacteria:</b> <i class="calibre3">Salmonella</i> spp., <i class="calibre3">Campylobacter</i>, <i class="calibre3">Listeria</i>, <i class="calibre3">Yersinia</i>, <i class="calibre3">Legionella</i> <span class="tfont">(</span><span class="tfont"><i class="calibre3">Lancet</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">6;387:376)</span>, <i class="calibre3">Rhodococcus</i>, <i class="calibre3">Nocardia</i>, TB, non-TB mycobacteria</p>
<p class="tabh"><b class="calibre4">Fungi:</b> <i class="calibre3">Candida</i>, <i class="calibre3">Crypto</i>, <i class="calibre3">Histo</i>, <i class="calibre3">Coccidio</i>, <i class="calibre3">Aspergillus</i>, <i class="calibre3">Pneumocystis, Zygomycetes</i> spp. and other molds</p>
<p class="tab"><b class="calibre4">Viruses:</b> HSV, VZV, CMV, EBV, JC virus, BK virus</p>
<p class="tabh"><b class="calibre4">Parasites:</b> <i class="calibre3">Toxoplasma</i>, <i class="calibre3">Cryptosporidium</i>, <i class="calibre3">Isospora</i>, <i class="calibre3">Microsporidia Babesia; Strongyloides</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Organ dysfunction</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Liver (esp. cirrhosis):</b> <i class="calibre3">Vibrio</i> spp., encapsulated bacteria</p>
<p class="tab"><b class="calibre4">ESRD:</b> impaired granulocyte fxn and CMI as above</p>
<p class="tab"><b class="calibre4">Iron overload (or deferoxamine Rx):</b> <i class="calibre3">Yersinia</i>, <i class="calibre3">Zygomycetes</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Biologics</b> (eg, TNF inhibitors, anti-B-cell Rx; ✔ for TB before starting)</p></td>
<td class="bg"><p class="tab"><b class="calibre4">Bacteria:</b> sepsis, septic arthritis, TB, NTM, <i class="calibre3">Listeria</i>, <i class="calibre3">Legionella</i></p>
<p class="tab"><b class="calibre4">Fungi:</b> <i class="calibre3">Pneumocystis, Histo, Coccidio, Aspergillus</i>, endemic fungi</p>
<p class="tab"><b class="calibre4">Viruses:</b> JC virus (PML), EBV, HSV, VZV, HBV</p>
<p class="tab"><b class="calibre4">Parasites:</b> <i class="calibre3">Strongyloides</i> reactivation</p></td>
</tr>
</table>
<p class="tsr">(<i class="calibre3">NEJM</i> 2007;357:2601; <i class="calibre3">Am J Med</i> 2007;120:764; <i class="calibre3">CID</i> 2011;53:798)</p>
<h2 class="ct"><a id="h85" class="calibre7"></a><a id="page_6-5" class="calibre7"></a><a href="part0002.html#rh94" class="calibre7">URINARY TRACT INFECTIONS</a></h2>
<p class="h2a">Definitions</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Uncomplicated:</b> confined to bladder (cystitis) or urethra. No s/s systemic infection.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Complicated:</b> extends beyond bladder with s/s incl. fever, rigors, malaise, flank pain, CVA tenderness, or pelvic/perineal pain in male. Includes pyelonephritis (inflam of renal parenchyma), perinephric abscess, prostatitis. Immunocompromised, men, poorly controlled DM, or those w/ urologic abnl (nephrolith., strictures, stents, diversions) are not automatically complicated, but at high risk. Follow closely w/ low threshold to escalate Rx. Pregnant &amp; renal Tx <i class="calibre3">are</i> complicated.</p>
<p class="h2a">Microbiology</p>
<p class="bl"><span class="sbl">•</span> Uncomplicated: <b class="calibre4"><i class="calibre3">E. coli</i></b> (80%), <i class="calibre3">Proteus</i>, <i class="calibre3">Klebsiella</i>, <i class="calibre3">S. saprophyticus</i> <span class="s1r">(<i class="calibre3">CID</i> 2004;39:75)</span>. In healthy, nonpregnant women, lactobacilli, enterococci, Group B strep and coag-neg staph (except <i class="calibre3">S. saprophyticus</i>) are likely <i class="calibre3">contaminants</i> <span class="s1r">(<i class="calibre3">Annals</i> 2012;156:ITC3)</span>.</p>
<p class="bl"><span class="sbl">•</span> Complicated: as above + PsA, enterococci, staph (uncommon 1º urinary pathogen w/o catheter or recent instrumentation; ? bacteremia w/ hematogenous spread). ↑ MDR.</p>
<p class="bl"><span class="sbl">•</span> Catheter-associated: <i class="calibre3">E. coli</i> most prevalent, but high risk for yeast (24%), MDR PsA, <i class="calibre3">Klebs</i>, <i class="calibre3">Enterococcus</i></p>
<p class="bl"><span class="sbl">•</span> Urethritis: <i class="calibre3">Chlamydia trachomatis, Neisseria gonorrhoeae, Ureaplasma urealyticum, Trichomonas vaginalis, Mycoplasma genitalium</i>, HSV</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cystitis: dysuria</b>, <b class="calibre4">urgency</b>, <b class="calibre4">frequency</b>, hematuria, suprapubic pain; fever <i class="calibre3">absent.</i> R/o vaginitis if symptoms of cystitis &amp; urethritis. Neurogenic bladder Pts may have atypical sx (↑ spasticity, autonomic dysreflexia, malaise).</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Urethritis:</b> similar to cystitis except <i class="calibre3">urethral discharge</i> can be present</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Prostatitis:</b> chronic: similar to cystitis except <i class="calibre3">symptoms of obstruction</i> (hesitancy, weak stream); acute: perineal pain, fever, tenderness on prostate exam</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pyelonephritis:</b> fever, chills, flank or back pain, nausea, vomiting, diarrhea</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Renal abscess</b> (intrarenal, perinephric): identical to pyelonephritis w/ <i class="calibre3">persistent fever despite appropriate antibiotics</i></p>
<p class="h2a">Diagnostic studies <span class="s">(<i class="calibre3">NEJM</i> 2016;374:562)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Urinalysis: pyuria</b> + bacteriuria ± hematuria ± nitrites</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Urine Cx</b> (clean-catch midstream or straight-cath)</p>
<p class="bl1">Obtain cx only if symptoms (although in ill Pts, can include ΔMS, autonomic instability)</p>
<p class="bl1">⊕ if: ≥10<sup class="calibre15">5</sup> CFU/mL in women, ≥10<sup class="calibre15">3</sup> CFU/mL in men. Counts may vary depending on dilution &amp; stage of infxn; interpret in context of sx and host.</p>
<p class="bl1">Pyuria &amp; ⊖ UCx = sterile pyuria → urethritis, nephritis, renal tuberculosis, foreign body</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Catheter-associated:</b> requires (1) s/s (incl atypical) + (2) urine Cx w/ 1 species ≥10<sup class="calibre15">3</sup> colonies from clean urine sample (after replacing Foley). Pyuria alone <i class="calibre3">not</i> sufficient to dx UTI in this setting (may be colonization, do not Rx or screen for asx bacteruria).</p>
<p class="bl"><span class="sbl">•</span> Blood cultures: obtain in febrile Pts; consider in complicated UTIs</p>
<p class="bl"><span class="sbl">•</span> For all men w/ UTI, consider prostatitis: ✔ prostate exam; UCx including 1<sup class="calibre15">st</sup> void, midstream, and ideally prostatic expressage &amp; postprostatic massage UCx</p>
<p class="bl"><span class="sbl">•</span> Abdominal CT: r/o abscess in Pts with pyelo who fail to defervesce after 72 h</p>
<p class="bl"><span class="sbl">•</span> Urologic w/u (renal U/S w/ PVR, abd CT, voiding cystography) if recurrent UTIs in men</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabc"><b class="calibre4">Treatment of UTIs</b> <span class="tfont">(</span><span class="tfont"><i class="calibre3">CID</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">0;50:625;</span> <span class="tfont"><i class="calibre3">JAMA</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">4;3</span><span class="tfont">1</span><span class="tfont">2:</span><span class="tfont">1</span><span class="tfont">677)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Scenario</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Empiric Treatment Guidelines</b> (choice can be individualized)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cystitis</b> <span class="tfont"><i class="calibre3">(JAMA</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">4;</span><span class="tfont">1</span><span class="tfont">6:</span><span class="tfont">1</span><span class="tfont">677)</span></p></td>
<td class="bg0-b"><p class="tabh">Uncomp: nitrofurantoin 100 mg × 5 d <i class="calibre3">or</i> TMP-SMX DS PO × 3 d <i class="calibre3">or</i> fosfomycin (3 g × 1). Refer to dosing guidelines for ↑ Cr.</p>
<p class="tab">Complicated: FQ or TMP-SMX PO × 7–14 d</p>
<p class="tab">FQ or TMP-SMX superior to β-lactams <span class="tfont">(</span><span class="tfont"><i class="calibre3">NEJM</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">2;366:</span><span class="tfont">1</span><span class="tfont">028)</span></p>
<p class="tab">Asx bacteriuria in pregnancy or prior to urologic surgery → abx × 3 d</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Catheterized</b></p></td>
<td class="bg0-b"><p class="tab">Await cultures if HD stable &amp; <b class="calibre4">remove (or exchange) catheter</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Urethritis</b></p></td>
<td class="bg0-b"><p class="tab">Treat for both <i class="calibre3">Neisseria</i> and <i class="calibre3">Chlamydia</i></p>
<p class="tab"><i class="calibre3">Neisseria:</i> CTX 250 mg IM × 1 and 1 g azithro PO × 1</p>
<p class="tab"><i class="calibre3">Chlamydia:</i> doxy 100 mg PO bid × 7 d <i class="calibre3">or</i> azithro 1 g PO × 1</p>
<p class="tab"><i class="calibre3">M. genitalium:</i> 1 g azithro PO × 1</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Prostatitis</b></p></td>
<td class="bg0-b"><p class="tab">FQ or TMP-SMX PO × 14–28 d (acute) or 6–12 wk (chronic)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pyelonephritis</b></p></td>
<td class="bg0-b"><p class="tab">OutPt: FQ × 7 d <i class="calibre3">or</i> TMP-SMX PO × 14 d <span class="tfont">(</span><span class="tfont"><i class="calibre3">Lancet</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">2;380:452)</span></p>
<p class="tabh">InPt: CTX <i class="calibre3">or</i> aminoglycoside × 14 d; if at risk for MDR pathogen cefepime, pip-tazo, carbapenem, or plazomicin <span class="tfont">(</span><span class="tfont"><i class="calibre3">NEJM</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">9;380:729)</span></p>
<p class="tabh">(Δ IV → PO when clinically improved &amp; afebrile 24–48 h, tailor to Cx)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Renal abscess</b></p></td>
<td class="bg"><p class="tab">Drainage + antibiotics as for pyelonephritis</p></td>
</tr>
</table>
<h2 class="ct"><a id="h86" class="calibre7"></a><a id="page_6-6" class="calibre7"></a><a href="part0002.html#rh95" class="calibre7">SOFT TISSUE AND BONE INFECTIONS</a></h2>
<p class="h">S<small class="calibre30">KIN AND</small> S<small class="calibre30">OFT</small> T<small class="calibre30">ISSUE</small> I<small class="calibre30">NFECTIONS</small> <span class="s1">(SSTI; <i class="calibre22">CID</i> 2014;59:e10)</span></p>
<p class="h2a">Clinical</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cellulitis:</b> infxn of dermis/sc fat, w/ erythema, edema, warmth, pain (rubor, tumor, calor, dolor)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Erysipelas:</b> infxn of upper dermis (more superficial than cellulitis), often caused by strep, w/ raised erythematous lesion w/ clear demarcation from normal skin</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Impetigo:</b> infxn of superficial layers, often caused by staph, typically in children, w/ purulent lesions, often on face/extrem, ± bullae, ± gold crust</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Lymphangitis:</b> proximal red streaking ± regional lymphadenopathy</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Toxic shock syndrome</b> can occur w/ staph or strep infxn. Fever, HA, N/V, diarrhea, myalgias, pharyngitis, diffuse rash w/ desquamation, HoTN, shock. BCx may be ⊖.</p>
<p class="h2a">Microbiology <span class="s">(<i class="calibre3">CID</i> 2014;59:e10)</span></p>
<p class="bl"><span class="sbl">•</span> Primarily strep and staph, including MRSA; may include GNRs in diabetics/immunosupp.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">MRSA</b> <span class="s1r">(<i class="calibre3">NEJM</i> 2005;352:1485 &amp; 2006;355:666)</span> causes up to 75% of purulent skin/soft tissue infxns, depending on local epi (rapidly increasing), often assoc. w/ purulent drainage or exudate. Often TMP-SMX sensitive; variably clindamycin sensitive (may falsely appear susceptible on lab testing, requires confirmation w/ D-test; <i class="calibre3">NEJM</i> 2007;357:380).</p>
<p class="bl"><span class="sbl">•</span> Bites: <b class="calibre4">skin (strep, staph)</b> and <b class="calibre4">oral flora</b> (incl anaerobes) + special exposures:</p>
<p class="imagef"><img src="../images/00105.jpeg" alt="" class="calibre2"/></p>
<p class="fn">*Cat scratch disease caused by Bartonella acquired via cat scratch or bite. Results in lymphadenitis.</p>
<p class="h2a">Diagnosis</p>
<p class="bl"><span class="sbl">•</span> Largely clinical diagnosis; BCx low yield (~5–10%) but useful if ⊕</p>
<p class="bl"><span class="sbl">•</span> Aspirate of bulla or pus from furuncle or pustule may provide microbiologic dx</p>
<p class="imagef"><img src="../images/00106.jpeg" alt="" class="calibre2"/></p>
<p class="fn">Mild: no systemic signs of infection; moderate: systemic signs; severe: SIRS or immunocompromised</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Limb elevation;</b> erythema may <i class="calibre3">worsen</i> after starting abx b/c bacterial killing → inflam.</p>
<p class="bl"><span class="sbl">•</span> In obese Pts, adequate drug dosing important to avoid treatment failure <span class="s1r">(<i class="calibre3">J Infect</i> 2012;2:128)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Duration:</b> 5 to up to 14 d. Take pictures &amp; draw margins to track progress.</p>
<p class="h"><a id="page_6-7" class="calibre7"></a>N<small class="calibre30">ECROTIZING</small> S<small class="calibre30">OFT</small> T<small class="calibre30">ISSUE</small> I<small class="calibre30">NFECTIONS</small> <span class="s1">(<i class="calibre22">NEJM</i> 2017;377:2253)</span></p>
<p class="h2a">Definition</p>
<p class="bl"><span class="sbl">•</span> Includes cellulitis, fasciitis, myositis, myonecrosis (gas gangrene).</p>
<p class="bl"><span class="sbl">•</span> Fulminant tissue destruction, systemic toxicity &amp; high mortality. <b class="calibre4">Surgical emergency</b>.</p>
<p class="h2a">Risk factors</p>
<p class="bl"><span class="sbl">•</span> Can affect healthy individuals via skin/mucosal breach or traumatic wound, but ↑ risk w/ DM, PVD, EtOH abuse, IVDU, cirrhosis, or other immunosupp.</p>
<p class="h2a">Microbiology</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Necrotizing fasciitis</b></p>
<p class="bl"><span class="sbl">•</span> Type I: polymicrobial (mixed aerobes &amp; anaerobes), typically in older Pts w/ above RFs. <b class="calibre4">Fournier’s gangrene</b> involves genitalia and/or perineum</p>
<p class="bl"><span class="sbl">•</span> Type II: monomicrobial, usually group A strep, less likely <i class="calibre3">Staph, Vibrio, Aero.</i>; a/w TSS</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Clostridial myonecrosis (gas gangrene):</b> <i class="calibre3">C. perfringens; C. septicum</i> (large Gram ⊕ rods w/ blunt ends on gram stain). A/w traumatic wounds that create an anaerobic environment ideal for <i class="calibre3">Clostridia</i>.</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Erythema, edema, warmth + <b class="calibre4">systemic illness</b> (fever, hemodynamic instability) <b class="calibre4">± crepitus</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rapid progression</b> of clinical signs</p>
<p class="bl"><span class="sbl">•</span> May see bullae, change in skin color (purple-red to blue-gray)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Pain out of proportion</b> to apparent cellulitis; skin hyperesthetic and later anesthetic</p>
<p class="h2a">Diagnosis</p>
<p class="bl"><span class="sbl">•</span> Clinical dx sufficient to initiate <b class="calibre4">urgent surgical exploration</b></p>
<p class="bl"><span class="sbl">•</span> Aspiration of necrotic center; BCx; Gram stain; lactic acid and CK for tissue necrosis</p>
<p class="bl"><span class="sbl">•</span> Imaging: <b class="calibre4">noncontrast CT</b>, but do not delay Rx/surgery <span class="s1r">(<i class="calibre3">Arch Surg</i> 2010;145:452)</span></p>
<p class="bl"><span class="sbl">•</span> Microbiologic dx from Gram stain and culture of surgical specimens</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">CID</i> 2014;60:169)</span></p>
<p class="bl"><span class="sbl">•</span> Urgent surgical exploration with debridement of necrotic tissue</p>
<p class="bl"><span class="sbl">•</span> Antibiotics: [vancomycin or linezolid] + [pip/tazo or carbapenem] + clinda for toxin inhibition Consider vanc + cefepime + metronidazole + clinda to avoid nephrotoxicity from pip/tazo Consider IVIG for GAS toxic shock; consult ID</p>
<p class="h">D<small class="calibre30">IABETIC</small> F<small class="calibre30">OOT</small> I<small class="calibre30">NFECTIONS</small></p>
<p class="cst"><i class="calibre3">Leading cause of DM-related hosp. days &amp; nontrauma amputations</i></p>
<p class="h2a">Microbiology and severity</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mild</b> (superficial ulcer, no involvement of deeper structures, erythema &lt;2 cm): usually <i class="calibre3">S. aureus</i> or aerobic streptococci</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Moderate</b> (ulcer with involvement of deeper structures, erythema &gt;2 cm): more likely to be chronic and polymicrobial (PsA, enterococci, <i class="calibre3">Enterobacter</i>, anaerobes)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Severe</b> (moderate + systemic sx infx): anaerobic streptococci, <i class="calibre3">Bacteroides</i>, <i class="calibre3">Clostridium</i></p>
<p class="h2a">Initial evaluation</p>
<p class="bl"><span class="sbl">•</span> Cleanse, debride, probe, and obtain deep anaerobic + aerobic cultures</p>
<p class="bl"><span class="sbl">•</span> Assess for PVD: sensation, pulses, ABIs</p>
<p class="h2a">Diagnosis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Deep tissue wound cx</b> at time of debridement (ideally prior to antibiotics). Avoid superficial swabs <span class="s1r">(<i class="calibre3">only</i> helpful if ⊕ for <i class="calibre3">S. aureus</i> and mild infxn)</span>.</p>
<p class="bl"><span class="sbl">•</span> For mod/severe: obtain blood cx, ESR, CRP</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Osteomyelitis should always be ruled out.</b> At ↑ risk if: grossly visible bone or able to probe to bone, ulcer &gt;2 cm, ulcer duration &gt;1–2 wk, ESR &gt;70. If suspicious for osteo, obtain plain films ± MRI (see below).</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">CID</i> 2012;54:e132)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mild infxn:</b> oral abx. Target skin flora (diclox, cephalexin, or amox/clav); use TMP-SMX or doxy for MRSA.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Mod/severe infxn:</b> IV abx. Target GPCs (vano, linezolid, or dapto) + GNRs (CTX, levo, or amp/sulb) ± anaerobes (metronidazole or clinda). Add PsA coverage (cefepime or pip-tazo) if: severe, immunocomp, neutropenic, water exposure, burn, puncture, nosocomial.</p>
<p class="bl"><span class="sbl">•</span> Elevation, non–weight-bearing status, wound care, glycemic control, Rx for venous insufficiency and arterial ischemia</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Many require surgery:</b> early, aggressive and repeated debridement; revascularization or amputation may be necessary</p>
<p class="h"><a id="page_6-8" class="calibre7"></a>O<small class="calibre30">STEOMYELITIS</small></p>
<p class="cst"><i class="calibre3">Infection of bone due to hematogenous seeding or direct spread from contiguous focus</i></p>
<p class="h2a">Microbiology <span class="s">(<i class="calibre3">Lancet</i> 2004;364:369)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hematogenous: <i class="calibre3">S. aureus</i></b>; mycobacterial infection of vertebral body = Pott’s disease</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Contiguous focus</b> (may be acute or chronic)</p>
<p class="bl1">open fracture, orthopedic surgery, etc.: <b class="calibre4"><i class="calibre3">S. aureus</i></b> and <b class="calibre4"><i class="calibre3">S. epi</i></b></p>
<p class="bl1">skin breakdown + vasc. insuffic. (eg, diabetic foot): <b class="calibre4">polymicrobial</b></p>
<p class="bl1">GU source (GNR, <i class="calibre3">Enterococcus</i>)</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Surrounding soft tissue compromise ± fistula to superficial skin</p>
<p class="bl"><span class="sbl">•</span> ± Fever, malaise, and night sweats (more common in hematogenous than contiguous)</p>
<p class="bl"><span class="sbl">•</span> Vertebral osteomyelitis (esp. IVDU): unremitting, focal back pain, usually febrile <span class="s1r">(<i class="calibre3">NEJM</i> 2010;362:1022)</span></p>
<p class="h2a">Diagnosis <span class="s">(<i class="calibre3">JAMA</i> 2008;299:806)</span></p>
<p class="bl"><span class="sbl">•</span> Goal is to obtain cx data of causative organism to avoid long-term empiric abx</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Bone biopsy</b> or <b class="calibre4">tissue cx</b> obtained surgically or via percutaneous biopsy (aspiration bx Se 30–74%) unless ⊕ blood cx. Do not rely on swabs of ulcers or fistulae drainage.</p>
<p class="bl"><span class="sbl">•</span> Physical exam: high suspicion in diabetic foot (see above) if can probe ulcer to bone or ulcer &gt;2 cm<sup class="calibre15">2</sup> (Sp 83%, 90% PPV)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Blood cultures before antibiotics</b> (more often ⊕ w/ acute hematogenous osteomyelitis)</p>
<p class="bl"><span class="sbl">•</span> CBC, CRP, ESR (&gt;70 greatly ↑ likelihood of osteo; <i class="calibre3">JAMA</i> 2008;299:806)</p>
<p class="bl"><span class="sbl">•</span> Imaging</p>
<p class="bl1">Plain radiographs: normal early in disease; lytic lesions seen after 2–6 wk</p>
<p class="bl1"><b class="calibre4">MRI:</b> most sensitive imaging study (overall Se 90%, Sp 82%; <i class="calibre3">Archives</i> 2007;167:125)</p>
<p class="bl1">CT: can demonstrate periosteal reaction and cortical and medullary destruction</p>
<p class="bl1">CT &amp; MRI very Se but ↓ Sp; false ⊕ if contig focus w/ periosteal reaction, Charcot Δs</p>
<p class="bl1">Radionuclide imaging: very Se but non-Sp (false ⊕ if soft tissue inflammation)</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Antibiotics:</b> based on cx data. Duration depends on Rx strategy/goals of Rx management (eg, 6 wks for vertebral osteo; <i class="calibre3">Lancet</i> 2015;385:875). After ≥7 days from either start of IV abx or surgery, if doing well consider (in consultation with ID!) Δ’ing IV to PO (if good bioavailability and bone penetration) <span class="s1r">(<i class="calibre3">NEJM</i> 2019;380:425)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Surgery</b> should be considered for any of the following: acute osteo that fails to respond to medical Rx, chronic osteo, complications of pyogenic vertebral osteo (eg, neurologic compromise, spinal instability, epidural abscess) or infected prosthesis</p>
<p class="h">E<small class="calibre30">PIDURAL</small> A<small class="calibre30">BSCESS</small></p>
<p class="h2a">Etiology</p>
<p class="bl"><span class="sbl">•</span> Hematogenous spread (<sup class="calibre15">2</sup>/<sub class="calibre8">3</sub>): skin infection, soft tissue (dental abscess) or endocarditis</p>
<p class="bl"><span class="sbl">•</span> Direct extension (⅓): vertebral osteo, sacral ulcer, spinal anesthesia or surgery, LP</p>
<p class="bl"><span class="sbl">•</span> Risk factors: diabetes, renal failure, alcoholism, IVDU, immunosupp.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4"><i class="calibre3">S. aureus</i></b> most common pathogen, increasing incidence of MRSA</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Back pain</b> (unremitting including midline) + often <b class="calibre4">fever</b> ± nerve root or cord signs</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">MRI</b></p>
<p class="bl"><span class="sbl">•</span> Aspiration of abscess fluid for Gram stain &amp; cx or operative Gram stain &amp; cx</p>
<p class="bl"><span class="sbl">•</span> Blood cx (frequently ⊖)</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Antibiotics</b> ± <b class="calibre4">surgery</b> (decompressive laminectomy and debridement) for failure to improve on medical Rx. Emergent surgery for early s/s of cord compression (w/ vertebral osteo and epidural abscess, may see paraplegia 48–72 h after first signs)</p>
<h2 class="ct"><a id="h87" class="calibre7"></a><a id="page_6-9" class="calibre7"></a><a href="part0002.html#rh96" class="calibre7">INFECTIONS OF THE NERVOUS SYSTEM</a></h2>
<p class="h">A<small class="calibre30">CUTE</small> B<small class="calibre30">ACTERIAL</small> M<small class="calibre30">ENINGITIS</small></p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">NEJM</i> 2006;354:44; <i class="calibre3">Lancet</i> 2012;380:1684)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Fever</b> (77%), <b class="calibre4">headache</b> (87%), <b class="calibre4">stiff neck</b> (31%), <b class="calibre4">photosensitivity</b>, Δ <b class="calibre4">MS</b> (69%) (defined as GCS &lt;14), <b class="calibre4">seizures</b> (5%); 2 of 4 (fever, HA, stiff neck, Δ MS) present in 95%</p>
<p class="bl"><span class="sbl">•</span> Presentation may be <i class="calibre3">atypical</i> (eg, lethargy w/o fever) in elderly and immunosupp.</p>
<p class="h2a">Physical exam</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Nuchal rigidity</b> (Se 31%), <b class="calibre4">Kernig’s sign</b> (Pt supine, hip flexed at 90°, knee flexed at 90°; ⊕ if passive extension of knee → resistance), <b class="calibre4">Brudzinski’s sign</b> (Pt supine and limbs supine; ⊕ if passive neck flexion → involuntary hip and/or knee flexion)</p>
<p class="bl1">nb, Kernig’s or Brudzinski’s signs ⊕ in only ~10% of Pts <span class="s1r">(<i class="calibre3">Lancet</i> 2012;380:1684)</span></p>
<p class="bl"><span class="sbl">•</span> ± Focal neuro findings (~30%; hemiparesis, aphasia, visual field cuts, CN palsies)</p>
<p class="bl"><span class="sbl">•</span> ± Funduscopic findings: papilledema, absent venous pulsations</p>
<p class="bl"><span class="sbl">•</span> ± HEENT findings: sinus tenderness, clear rhinorrhea (CSF leak)</p>
<p class="bl"><span class="sbl">•</span> ± Skin findings: petechial rash (<i class="calibre3">N. meningitidis</i>), genital or oral ulcers (HSV)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Microbiology in Bacterial Meningitis</b> <span class="tfont1">(<i class="calibre3">NEJM</i> 2011;364:2016)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Etiology</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Comments</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4"><i class="calibre3">S. pneumoniae</i></b> (30–60%)</p></td>
<td class="bg0-b"><p class="tab">Assess for distant infxn (eg, Osler’s triad = meningitis, PNA, IE)</p>
<p class="tab">Drug-resistant <i class="calibre3">S. pneumoniae:</i></p>
<p class="tabh1">~40% PCN-resistant (even <i class="calibre3">intermediate</i> resistance problematic)</p>
<p class="tabh1">~&lt;10% 3<sup class="calibre35">rd</sup>-gen. cephalosporin-resistant</p>
<p class="tab">Vaccine may have reduced rate of invasive disease</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4"><i class="calibre3">N. meningitidis</i></b> (10–35%)</p></td>
<td class="bg0-b"><p class="tabh">Primarily in those &lt;30 y; may be a/w petechiae or purpura. Deficiencies in terminal complement predispose to recurrent meningococcemia &amp; rarely meningitis.</p>
<p class="tabh">Vaccine rec for all adolescents, college freshmen living in dorm, military recruits, s/p splenectomy or C5-9 deficiency</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4"><i class="calibre3">H. influenzae</i></b> (&lt;5%)</p></td>
<td class="bg0-b"><p class="tabh">↓ Incidence in children b/c vaccine. Look for risk factors in adults (eg, CSF leak, neurosurgical procedure, trauma, mastoiditis).</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><i class="calibre3">L. monocytogenes</i> (5–10%)</p></td>
<td class="bg0-b"><p class="tabh">↑ Incid in elderly, alcoholics or Pts w/ cancer, immunosupp. or iron overload. Outbreaks a/w contaminated dairy &amp; raw vegetables. Despite name, a/w <i class="calibre3">poly-predominant</i> pleocytosis.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">GNRs (1–10%)</p></td>
<td class="bg0-b"><p class="tabh">Usually health care associated, postprocedure or in elderly or immunosuppressed</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><i class="calibre3">Staphylococci</i> (5%)</p></td>
<td class="bg0-b"><p class="tabh">Seen with indwelling CSF shunt (<i class="calibre3">S. epidermidis</i>) or following neurosurgery or head trauma (<i class="calibre3">S. aureus</i>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Mixed infection</p></td>
<td class="bg0-b"><p class="tab">Suspect parameningeal focus or CSF leak</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Fungal</p></td>
<td class="bg"><p class="tab">Seen if immunosuppressed or after neurosurgery</p></td>
</tr>
</table>
<p class="h2a">Sequential approach to bacterial meningitis</p>
<p class="bl">(1) Stat <b class="calibre4">BCx</b> → <b class="calibre4">antibiotics</b> + <b class="calibre4">corticosteroids</b> (see below)</p>
<p class="bl">(2) Consider CT head (if indicated, see below)</p>
<p class="bl">(3) <b class="calibre4">LP</b> (if not contraindicated); yield of CSF cx unlikely to be changed if obtained w/in ~4 h of initiation of abx</p>
<p class="h2a">Diagnostic studies <span class="s">(<i class="calibre3">NEJM</i> 2017;388:3036)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Blood cultures</b> ×<b class="calibre4">2 <i class="calibre3">before abx</i></b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">WBC count:</b> &gt;10,000 in &gt;90% of bacterial meningitis in healthy hosts</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Head CT</b> to r/o mass effect before LP <i class="calibre3">if</i> ≥1 high-risk feature: immunosupp., h/o CNS disease, new-onset seizure, focal neuro findings, papilledema <span class="s1r">(<i class="calibre3">CID</i> 2004;39:1267)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Lumbar puncture</b> <span class="s1r">(<i class="calibre3">NEJM</i> 2006;355:e12)</span></p>
<p class="bl1"><b class="calibre4">CSF Gram stain</b> has 30–90% Se; cx 80–90% Se if LP done prior to abx</p>
<p class="bl1">opening pressure typically ↑ in bact meningitis; must measure w/ Pt’s legs extended</p>
<p class="bl1"><i class="calibre3">rule of 2s:</i> CSF WBC &gt;2k, glc &lt;20, &amp; TP &gt;200 has &gt;98% Sp for bacterial meningitis</p>
<p class="bl1">repeat LP only if no clinical response after 48 h of appropriate abx or CSF shunt</p>
<p class="bl"><span class="sbl">•</span> Additional CSF studies based on clinical suspicion: AFB smear &amp; cx, India ink prep, cryptococcal Ag, fungal cx, VDRL, PCR (HSV, VZV, enteroviral), cytology</p>
<p class="bl"><span class="sbl">•</span> Metagenomic next-generation sequencing ↑ dx yield <span class="s1r">(<i class="calibre3">NEJM</i> 2019;380:2327)</span></p>
<p class="image1"><a id="page_6-10" class="calibre1"></a><img src="../images/00107.jpeg" alt="" class="calibre2"/></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre16"/>
<col class="calibre20"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Treatment of Bacterial Meningitis</b> <span class="tfont1">(<i class="calibre3">Lancet</i> 2012;380:1693)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Clinical Scenario</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Empiric Treatment Guidelines</b><a id="st9" class="calibre1"></a><a href="part0011.html#sst9" class="calibre1">*</a></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Normal adult</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Ceftriaxone 2 g IV q12h <sub class="calibre13">+</sub> vancomycin 15–20 mg/kg IV q12h</b></p>
<p class="tab">If &gt;50 y or alcoholic: add ampicillin 2 g IV q4h for <i class="calibre3">Listeria</i></p>
<p class="tabh">β-lactam allergy: substitute cipro 400 mg q8h or aztreonam 2 g q6h for CTX. Substitute TMP/SMX for amp.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Immunosuppressed</b></p></td>
<td class="bg0-b"><p class="tab">Ampicillin + ceftazidime 2 g IV q8h + vancomycin</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">CSF shunts</b>, <b class="calibre4">recent neurosurgery, or head trauma</b></p></td>
<td class="bg0-b"><p class="tab">Vancomycin + ceftazidime 2 g IV q8h <span class="tfont">(</span><span class="tfont"><i class="calibre3">NEJM</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">0;362:</span><span class="tfont">1</span><span class="tfont">46)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b" colspan="2"><p class="tab"><b class="calibre4">Corticosteroids:</b> dexamethasone 10 mg IV q6h × 4 d → ↓ neuro disability &amp; mortality by ~50% w/ <i class="calibre3">S. pneumo</i> &amp; GCS 8–11. Consider steroids in all bacterial meningitis prior to organism identification. <b class="calibre4">Must start before or w/ 1st dose of abx</b> <span class="tfont">(</span><span class="tfont"><i class="calibre3">NEJM</i></span> <span class="tfont">2002;347:</span><span class="tfont">1</span><span class="tfont">549).</span></p>
<p class="tab">Nb, do <i class="calibre3">not</i> give steroids in cryptococcal meningitis <span class="tfont">(</span><span class="tfont"><i class="calibre3">NEJM</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">6;374:542).</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b" colspan="2"><p class="tab"><b class="calibre4">Prophylaxis:</b> rifampin (600 mg PO bid × 2 d) or ciprofloxacin (500 mg PO × 1) or ceftriaxone (250 mg IM × 1) for close contacts of Pt w/ <i class="calibre3">N. meningitidis</i> meningitis</p></td>
</tr>
<tr class="calibre12">
<td class="bg" colspan="2"><p class="tab"><b class="calibre4">Precautions:</b> droplet precautions until <i class="calibre3">N. meningitidis</i> is r/o</p></td>
</tr>
</table>
<p class="tsr"><a id="sst9" class="calibre1"></a><a href="part0011.html#st9" class="calibre1">*</a>When possible, organism-directed Rx, guided by sensitivities or local patterns of drug resistance should be used. In mouse model, Cftx + Ab directed against plgR and PECAM (blood–brain barrier receptors that allow <i class="calibre3">S. Pneumoniae</i> to enter) → ↓ bacteria in the brain &amp; less inflammation (<i class="calibre3">J Infect Dis</i> 2018; 218:476).</p>
<p class="h2a">Prognosis</p>
<p class="bl"><span class="sbl">•</span> For community-acquired <i class="calibre3">S. pneumo</i> mort. 19–37%; 30% have long-term neuro sequelae</p>
<p class="h">A<small class="calibre30">SEPTIC</small> M<small class="calibre30">ENINGITIS</small></p>
<p class="h2a">Definition</p>
<p class="bl"><span class="sbl">•</span> CSF pleocytosis w/ ⊖ blood &amp; CSF cx; typically lymphocyte predominant</p>
<p class="bl"><span class="sbl">•</span> Less likely to be bacterial, but can be infectious or noninfectious</p>
<p class="h2a">Etiologies <span class="s">(<i class="calibre3">Neurology</i> 2006;66:75)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Viral:</b> enteroviruses [most common; if CSF ⊖ &amp; PCR not available, test nonsterile sites (eg, nasopharyngeal, rectum)] to help r/o], HIV, HSV (type 2 &gt; 1), VZV, mumps, lymphocytic choriomeningitis virus, encephalitis viruses, adenovirus, polio, CMV, EBV, WNV</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Parameningeal focus of infection</b> (eg, brain abscess, epidural abscess, septic thrombophlebitis of dural venous sinuses or subdural empyema)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Partially treated bacterial meningitis</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">TB</b>, <b class="calibre4">fungal</b>, <b class="calibre4">spirochetal</b> (Lyme, syphilis, leptospirosis), <b class="calibre4">rickettsial</b>, <i class="calibre3">Coxiella</i>, <i class="calibre3">Ehrlichia</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Medications:</b> TMP/SMX, NSAIDs, IVIG, PCN, INH, lamotrigine</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Systemic illness:</b> SLE, sarcoidosis, Behçet’s, Sjögren’s syndrome, RA</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Neoplasm:</b> intracranial tumors (or cysts), lymphomatous or carcinomatous meningitis (CSF cytology or flow may be reactive and dx may require meningeal bx)</p>
<p class="h2a">Empiric treatment</p>
<p class="bl"><span class="sbl">•</span> No abx if suspect viral (cell count &lt;500 w/ &gt;50% lymphs, TP &lt;80–100 mg/dL, normal glc, ⊖ Gram stain, not elderly/immunosupp.); o/w start empiric abx, wait for cx data</p>
<p class="bl"><span class="sbl">•</span> If suspect MTb: antimycobacterial Rx + dexamethasone <span class="s1r">(<i class="calibre3">NEJM</i> 2004;351:1741)</span></p>
<p class="bl"><span class="sbl">•</span> If suspect fungal: ampho lipid formulation, ± 5-fluorouracil</p>
<p class="h"><a id="page_6-11" class="calibre7"></a>E<small class="calibre30">NCEPHALITIS</small> <span class="s1">(<i class="calibre22">NEJM</i> 2018;379:557)</span></p>
<p class="h2a">Definition</p>
<p class="bl"><span class="sbl">•</span> Infection of brain parenchyma with evidence of neurologic dysfunction</p>
<p class="h2a">Etiologies <span class="s">(specific etiology found in</span> &lt;<span class="s">20% of cases; <i class="calibre3">Neurology</i> 2006;66:75; <i class="calibre3">CID</i> 2008;47:303)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">HSV-1</b> all ages/seasons. If sxs recur after Rx, consider viral relapse vs. autoimmune encephalitis b/c high rates of autoimmune disease wks later <span class="s1r">(<i class="calibre3">Lancet Neurol</i> 2018;17:760)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">VZV</b> 1° or reactivation; ± vesicular rash; all ages (favors elderly), all seasons</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Arboviruses:</b> West Nile, Eastern/Western equine, St. Louis, Japanese, Powassan <span class="s1r">(<i class="calibre3">NEJM</i> 2005;353:287)</span>: fever, HA, <b class="calibre4">flaccid paralysis</b>, rash. Risk factors for severe renal dis., cancer, EtOH, DM, HTN <span class="s1r">(<i class="calibre3">Am J Trop Med Hyg</i> 2012;87:179)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Enteroviruses</b> (coxsackie, echo): viral syndrome; peaks in late summer/early fall</p>
<p class="bl"><span class="sbl">•</span> Others: CMV, EBV, HIV, JC virus (PML), measles, mumps, rubella, rabies, flu, adenovirus</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Non-infectious</b>: autoimmune/paraneoplastic (anti-NMDAR, anti-Hu, anti-Ma2, anti-CRMP5, anti-mGluR5), endocarditis, brain abscess, toxoplasmosis, TB, toxins, vasculitis, Whipple’s disease, subdural hematoma, post-infxn demyelination (eg, ADEM), seizure</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Fever</b>, <b class="calibre4">HA,</b> Δ <b class="calibre4">MS</b>, ± seizures and <b class="calibre4">focal neuro findings</b> (latter atypical for viral <i class="calibre3">meningitis</i>)</p>
<p class="h2a">Diagnostic studies <span class="s">(<i class="calibre3">CID</i> 2013;57:1114)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Lumbar puncture:</b> lymphocytic pleocytosis; PCR for HSV (95% Se &amp; Sp at 2–3 d), VZV, CMV, EBV, HIV, JC, adeno/enterovirus, W. Nile (&lt;60% Se); W. Nile CSF IgM 80% Se</p>
<p class="bl"><span class="sbl">•</span> Consider testing for autoimmune etiologies (anti-NMDAR, etc.) in approp. setting</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">MRI</b> (CT if unavail.); HSV w/temporal lobe involvement, W. Nile w/ thalamic hyperintensity</p>
<p class="bl"><span class="sbl">•</span> EEG to r/o seizure; findings in encephalitis are nonspecific (temporal lobe focus in HSV)</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> HSV, VZV: acyclovir 10 mg/kg IV q8h (often empiric Rx given frequency of HSV/VZV)</p>
<p class="bl"><span class="sbl">•</span> CMV: ganciclovir ± foscarnet; supportive care for most other etiologies</p>
<p class="h">B<small class="calibre30">ELL</small>’<small class="calibre30">S</small> P<small class="calibre30">ALSY</small></p>
<p class="h2a">Definition &amp; etiology</p>
<p class="bl"><span class="sbl">•</span> Acute idiopathic unilat. <b class="calibre4">facial nerve palsy</b> (CN VII), often presumed HSV-1 reactivation</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> Unilateral <b class="calibre4">facial muscle weakness</b>, <b class="calibre4">hyperacusis</b>, ↓ taste/lacrimation/salivation</p>
<p class="h2a">Diagnosis</p>
<p class="bl"><span class="sbl">•</span> Dx of exclusion: r/o brainstem lesion, Lyme (often bilateral), zoster (incl <i class="calibre3">sine herpete</i>), HIV/AIDS, sarcoid (often bilateral)</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">NEJM</i> 2007;357:1598; <i class="calibre3">JAMA</i> 2009;302:985)</span></p>
<p class="bl"><span class="sbl">•</span> ~80% recover spontaneously by 9 mo (much lower rate in DM)</p>
<p class="bl"><span class="sbl">•</span> Corticosteroids (prednisolone 25 mg PO bid × 10 d) started w/in 72 h of sx onset improve odds of recovery (note: no conclusive data for use in DM, immunosupp.)</p>
<p class="bl"><span class="sbl">•</span> No conclusive data to support the use of acyclovir or valacyclovir</p>
<p class="h">Z<small class="calibre30">OSTER</small></p>
<p class="h2a">Definition &amp; etiology</p>
<p class="bl"><span class="sbl">•</span> Zoster = herpes zoster = shingles: acute, unilat., <b class="calibre4">painful dermatomal skin eruption</b></p>
<p class="bl"><span class="sbl">•</span> VZV reactivation in peripheral nerve distribution from latency in dorsal root ganglion</p>
<p class="h2a">Clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Neuritic pain in a dermatomal distribution</b>, then acute <b class="calibre4">dermatomal eruption of clustered rash</b> (vesicles &gt; papules/pustules &gt; macules) in varying stages of evolution</p>
<p class="bl"><span class="sbl">•</span> Consecutive dermatomes may be seen in all Pts; more widespread in immunosupp.</p>
<p class="bl"><span class="sbl">•</span> Lesions in V1 distribution of facial nerve require urgent ophthalmologic evaluation</p>
<p class="bl"><span class="sbl">•</span> Post-herpetic neuralgia (PHN) = severe pain lasting &gt;90 d after episode; may last mos to y, more frequent w/ ↑ age and delay of antiviral Rx</p>
<p class="h2a">Diagnosis</p>
<p class="bl"><span class="sbl">•</span> Appearance of rash; DFA is most Se from scrape of newly unroofed vesicle. Tzanck does not distinguish HSV or VZV, cx insensitive for VZV (unlike HSV).</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> Rx if can initiate <b class="calibre4">w/in 72 h of skin lesions</b> in healthy Pt or at <b class="calibre4"><i class="calibre3">any time</i> in immunosupp</b></p>
<p class="bl"><span class="sbl">•</span> Valacyclovir or famciclovir × 7–14 d, or until lesions fully crusted; acyclovir 10 mg/kg IV q8h if dissem. or high-risk Pt (medically ill, immunosupp., V1 zoster w/ ophthalmic s/s, etc.)</p>
<p class="bl"><span class="sbl">•</span> Prevention: Shingrix approved for Pts &gt;50 y. 2 doses separated by 2–6 mos (97% effective at preventing shingles, also ↓ post-herpetic neuralgia).</p>
<h2 class="ct"><a id="h88" class="calibre7"></a><a id="page_6-12" class="calibre7"></a><a href="part0002.html#rh97" class="calibre7">BACTEREMIA &amp; ENDOCARDITIS</a></h2>
<p class="h">B<small class="calibre30">ACTEREMIA</small></p>
<p class="h2a">Etiologies</p>
<p class="bl"><span class="sbl">•</span> 1° infxn due to direct inoculation of the blood, frequently assoc w/ intravascular catheters. Catheter-related bloodstream infection = same org from peripheral cx <i class="calibre3">and</i> cath tip cx <i class="calibre3">or</i> cx drawn from catheter <span class="s">(<i class="calibre3">CID</i> 2009;49:1)</span>.</p>
<p class="bl"><span class="sbl">•</span> 2° infxn due to infection in another site (eg, UTI, lung, biliary tree, skin) spreading to blood</p>
<p class="h2a">Microbiology</p>
<p class="bl"><span class="sbl">•</span> Coag-neg staph 34%, <i class="calibre3">S. aureus</i> 10%, enterococci 16%, <i class="calibre3">Candida</i> 12%, GNRs 5%</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Clostridium septicum</i>, <i class="calibre3">Bacteroides</i>, &amp; <i class="calibre3">S. bovis</i> a/w colon ca <span class="s1r">(<i class="calibre3">Gastro</i> 2018;155:383)</span></p>
<p class="bl"><span class="sbl">•</span> Bacteremia with encapsulated organisms (<i class="calibre3">S. pneumo, Neisseria, Haemophilus</i>, Group A strep) may indicate 1° immunodeficiency <span class="s1r">(<i class="calibre3">Clin Microbiol Infect</i> 2017;8:576)</span></p>
<p class="h2a">Risk factors for true bacteremia <span class="s">(<i class="calibre3">JAMA</i> 2012;308:502)</span></p>
<p class="bl"><span class="sbl">•</span> Fever, <b class="calibre4">shaking chills</b> and poor food consumption <span class="s1r">(<i class="calibre3">J Hosp Med</i> 2017;12:510)</span>, SIRS (96% Se), IVDU, comorbidities, immunosupp, indwelling lines</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Organism</b></p>
<p class="bl1">more likely pathogenic: <i class="calibre3">S. aureus</i>, β-hemolytic strep, enterococci, GNR, <i class="calibre3">S. pneumo, Neisseria</i></p>
<p class="bl1">less likely pathogenic: coag-neg staph (~10%), diphtheroids, <i class="calibre3">Propionibacterium</i> (~0%)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Time to growth:</b> &lt;24 h → higher risk, &gt;72 h → lower risk (except for slow-growing organisms such as HACEK group)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Factors increasing likelihood of endocarditis:</b> high-grade bacteremia w/o source, persisting after line removal or drainage of focal source, in hosts at risk for endocarditis or w/ organisms known to cause IE; emboli</p>
<p class="h2a">Diagnosis</p>
<p class="bl"><span class="sbl">•</span> Obtain BCx prior to abx if possible, ≥2 sets (2 bottles in each set, each w/ 10 cc blood)</p>
<p class="bl"><span class="sbl">•</span> If proven bacteremia, daily surveillance cxs until 48 hrs of ⊖ cxs. May not need for GNRs <span class="s1r">(<i class="calibre3">ClD</i> 2017;65:1776)</span>.</p>
<p class="bl"><span class="sbl">•</span> If <i class="calibre3">S. aureus</i> or <i class="calibre3">S. lugdunensis</i> obtain <b class="calibre4">TEE</b>. TTE for high-grade Strep bacteremia. No need for routine echos for GNR bacteremia.</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> Antibiotics based on Gram stain/culture results; tailor abx to sensitivities</p>
<p class="bl1">empiric therapy for GPC: vanco to cover coag-neg staph and MRSA while awaiting sensi</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">S. aureus</i> bacteremia: ID consult associated with lower mortality <span class="s1r">(<i class="calibre3">ClD</i> 2015;60:1451)</span>.</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Short-Term Central Venous Catheter-Related Bloodstream Infections</b> <span class="tfont1">(</span><span class="tfont1"><i class="calibre3">CID</i></span> <span class="tfont1">2009;49:</span><span class="tfont">1</span><span class="tfont1">)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4"><i class="calibre3">S. aureus</i></b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Risk of endocarditis in bacteremia:</b> ~25% <span class="tfont">(</span><span class="tfont"><i class="calibre3">JACC</i></span> <span class="tfont">1</span><span class="tfont">997;30:</span><span class="tfont">1</span><span class="tfont">072)</span></p>
<p class="tabh">D/c CVC, TEE to r/o endocarditis; if TEE ⊖ <i class="calibre3">and</i> not immunosupp. <i class="calibre3">and</i> no intravasc prosthesis, Rx × 2 wk from first ⊖ BCx. If no echo obtained, Rx × 4–6 wk.</p>
<p class="tab"><b class="calibre4">Preferred abx:</b> MSSA → nafcillin or cefazolin; MRSA → vancomycin</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Coag-neg staphylococci</b></p></td>
<td class="bg0-b"><p class="tabh">May consider keeping catheter. Catheter retention does not ↓ rate of bacteremia resolution, but a/w ↑ rate of recurrence <span class="tfont">(</span><span class="tfont"><i class="calibre3">CID</i></span> <span class="tfont">2009;49:</span><span class="tfont">11</span><span class="tfont">87)</span>.</p>
<p class="tab">If catheter left in place, Rx × 10–14 d and consider abx or ethanol lock</p>
<p class="tab">If catheter d/c, Rx × 5–7 d</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4"><i class="calibre3">Enterococcus</i></b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">D/c catheter</b> &amp; Rx × 7–14 d</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">GNR</b></p></td>
<td class="bg0-b"><p class="tab">Rx × 7–14 d. Abx based on sensitivities. <b class="calibre4">D/c catheter</b> if <i class="calibre3">Pseudomonas.</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Fungi</b></p></td>
<td class="bg"><p class="tab"><b class="calibre4">D/c catheter</b> &amp; Rx × 14 d from first ⊖ BCx</p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Persistently</b> ⊕ <b class="calibre4">BCx:</b> d/c indwelling catheters, consider metastatic infxn, infected thrombosis or infected prosthetic material (joint, abscess, vascular graft, PPM, etc.)</p>
<p class="h">B<small class="calibre30">ACTERIAL</small> E<small class="calibre30">NDOCARDITIS</small></p>
<p class="h2a">Definition</p>
<p class="bl"><span class="sbl">•</span> Infection of endothelium of heart (including but not limited to the valves)</p>
<p class="h2a">Predisposing conditions</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Abnormal valve</b></p>
<p class="bl1"><i class="calibre3">High risk:</i> prior endocarditis, prosthesis, cyanotic congenital heart (unrepaired), VADs, rheumatic heart disease, AoV disease (incl. bicuspid)</p>
<p class="bl1"><i class="calibre3">Medium risk:</i> MV disease (including MVP w/ MR or thickened leaflet), HCMP</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Risk of bacteremia:</b> IVDU, indwelling venous catheters, poor dentition, hemodialysis, DM, prosthetic material in heart (eg, pacemaker, ICD, graft)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><a id="page_6-13" class="calibre1"></a><p class="tabheadc"><b class="calibre4">Modified Duke Criteria</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Major</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Minor</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br">
<p class="bull-t"><span class="sbull-t">•</span> <b class="calibre4">BCx</b> with common endocarditis pathogen (grown in 2 separate cultures)</p> 
<p class="bull-t"><span class="sbull-t">•</span> <i class="calibre3">Coxiella</i> serology ≥1:800</p> 
<p class="bull-t"><span class="sbull-t">•</span> <b class="calibre4">Endocardial involvement</b>, w/ either: <b class="calibre4">echocardiogram</b> w/ vegetation, abscess, or prosthetic dehiscence<br class="calibre6"/><b class="calibre4">new valvular regurgitation</b></p></td>
<td class="bg0-b">
<p class="bull-t"><span class="sbull-t">•</span> Predisposing condition (see above)</p> 
<p class="bull-t"><span class="sbull-t">•</span> Fever</p> 
<p class="bull-t"><span class="sbull-t">•</span> <b class="calibre4">Vascular phenomena:</b> septic arterial or pulmonary emboli, mycotic aneurysms, ICH, Janeway lesions</p> 
<p class="bull-t"><span class="sbull-t">•</span> <b class="calibre4">Immune phenomena:</b> ⊕ RF, GN, Osler’s nodes, Roth spots</p> 
<p class="bull-t"><span class="sbull-t">•</span> ⊕ <b class="calibre4">BCx</b> not meeting major criteria</p></td>
</tr>
<tr class="calibre12">
<td class="bg" colspan="2"><p class="tab">Definitive (ie, highly probable): 2 major <i class="calibre3">or</i> 1 major + 3 minor <i class="calibre3">or</i> 5 minor criteria</p>
<p class="tab">Possible: 1 major + 1 minor <i class="calibre3">or</i> 3 minor criteria</p></td>
</tr>
</table>
<p class="tsr">Se ~90%, Sp &gt;95%, NPV ≥92% (<i class="calibre3">CID</i> 2000;30:633). *Serologic or molecular tests for other known agents of Cx ⊝ endocarditis (see below) not yet included as major criterion, but may help dx.</p>
<p class="imagef"><img src="../images/00108.jpeg" alt="" class="calibre2"/></p>
<p class="fn"><sup class="calibre35">a</sup>↑ risk w/ DM, indwelling lines, immunosupp. <sup class="calibre35">b</sup>Cx ⊖ = abiotrophic strep, HACEK <span class="tfont1">(<i class="calibre3">Haemophilus para-influenzae</i> &amp; <i class="calibre3">aphrophilus, Actinobacillus, Cardiobacterium, Eikenella</i> and <i class="calibre3">Kingella</i>)</span>, <i class="calibre3">T. whipplei</i>, <i class="calibre3">Bartonella, Coxiella, Chlamydia, Legionella, Brucella</i> <span class="tfont1">(<i class="calibre3">JAMA</i> 2007;297:1354; <i class="calibre3">Annals</i> 2007;147:829; <i class="calibre3">J Clin Microbiol</i> 2012;50:216)</span></p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">Lancet</i> 2016;387:882)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Persistent bacteremia: fever</b> (80–90%), rigors, night sweats, anorexia, wt loss, fatigue</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Valvular or perivalvular infection:</b> CHF, conduction abnormalities</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Septic emboli:</b> stroke, PE (if right-sided), mycotic aneurysm, MI (coronary artery embolism), CNS, kidneys, spleen, joints</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Immune complex phenomena:</b> arthritis, glomerulonephritis, ⊕ RF, ↑ ESR</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">Subacute</i> (less-virulent pathogens) can p/w fatigue, nonspecific sx in Pts w/o risk factors</p>
<p class="h2a">Physical exam</p>
<p class="bl"><span class="sbl">•</span> HEENT: <b class="calibre4">Roth spots</b> (retinal hemorrhage + pale center), <b class="calibre4">petechiae</b> (conjunctivae, palate)</p>
<p class="bl"><span class="sbl">•</span> Cardiac: <b class="calibre4">murmur</b> (85%), <b class="calibre4">new valve regurgitation</b> (40–85%) ± thrill (fenestrated valve or ruptured chordae), muffled sounds (PV). <i class="calibre3">Frequent exams</i> for Δ murmurs, s/s CHF.</p>
<p class="bl"><span class="sbl">•</span> Extremities</p>
<p class="bl1"><b class="calibre4">Janeway lesions</b> (septic emboli → nontender, hemorrhagic macules on palms or soles)</p>
<p class="bl1"><b class="calibre4">Osler’s nodes</b> (immune complexes → tender nodules on pads of digits)</p>
<p class="bl1"><i class="calibre3">proximal</i> nail bed splinter hemorrhages (8–15%); petechiae (33%); clubbing; arthritis</p>
<p class="bl"><span class="sbl">•</span> Δ MS or focal deficits, vertebral tenderness</p>
<p class="bl"><span class="sbl">•</span> Devices: erythema, tenderness or drainage at catheter site, PM/ICD pocket tenderness</p>
<p class="h2a">Diagnosis <span class="s">(<i class="calibre3">CID</i> 2010;51:131; <i class="calibre3">EHJ</i> 2015;36:3075; <i class="calibre3">Circ</i> 2015;132:1435)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Blood cultures</b> (<i class="calibre3">before abx</i>): 3 sets (aerobic &amp; anaerobic bottles) from different sites, ideally spaced ≥1 h apart. ✔ BCx (at least 2 sets) after appropriate abx have been initiated to document clearance; repeat q24–48h until ⊖.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">ECG</b> (on admission and at regular intervals) to assess for new conduction abnormalities</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Echocardiogram:</b> <i class="calibre3">TTE in all</i>. Obtain <b class="calibre4">TEE</b> if (i) TTE nondx (ii) TTE ⊖ but high suspicion, (iii) high-risk (prosthetic valve, prior IE, congenital heart dis.), or (iv) suspect progressive or invasive infxn (eg, persistent bacteremia or fever, new conduction abnl, etc.)</p>
<p class="imagef"><img src="../images/00109.jpeg" alt="" class="calibre2"/></p>
<p class="fn">(<i class="calibre3">Mayo Clin Proc</i> 2014;89:799; <i class="calibre3">Circ</i> 2015;132:1435; <i class="calibre3">Eur Radiol</i> 2015; 25:2125; <i class="calibre3">J Am Soc Echo</i> 2016;29:315)</p>
<p class="bl"><span class="sbl">•</span> Addition of PET/CT or MRI helpful to assess for periannular complications in PVE</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Brain/spine imaging</b> necessary in those who develop severe HA, neurologic deficits, meningeal signs. Consider in any patient with left-sided endocarditis <span class="s1r">(<i class="calibre3">Circ</i> 2015;132:1435)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cx</b> ⊖ <b class="calibre4">endocarditis:</b> may be due to abx prior to BCx. PCR, bacterial 16S ribosomal RNA, serol. may be helpful. Detailed hx: animal exposure, travel, unpast. dairy, etc. ID eval.</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre10"/>
<col class="calibre11"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><a id="page_6-14" class="calibre1"></a><p class="tabheadc"><b class="calibre4">Treatment</b> <span class="tfont1">(<i class="calibre3">Circ</i> 2015;132:1435)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Organism</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Specific Considerations</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Empiric</b></p></td>
<td class="bg0-b"><p class="tab">NVE or PVE &gt;12 mo post-op: Vanc + CTX PVE &lt;12 mo post op: Vanc + CTX + gent</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><i class="calibre3">Strep</i></p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">S. bovis</i> a/w colon cancer. Penicillin, Amp, CTX</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><i class="calibre3">Staph</i></p></td>
<td class="bg0-b">
<p class="bull-t"><span class="sbull-t">•</span> MRSA: vanc or dapto; MSSA: nafcillin or cefazolin</p> 
<p class="bull-t"><span class="sbull-t">•</span> Obtain ID consult</p> 
<p class="bull-t"><span class="sbull-t">•</span> Vanc inferior to beta lactam for long-term MSSA Rx</p> 
<p class="bull-t"><span class="sbull-t">•</span> For PCN allergy w/ MSSA, undergo desensitization</p> 
<p class="bull-t"><span class="sbull-t">•</span> Do not use cefazolin for CNS involvement b/c poor penetration</p> 
<p class="bull-t"><span class="sbull-t">•</span> Rif (+ AG × 2 wk to prevent resistance) should be added in PVE</p> 
<p class="bull-t"><span class="sbull-t">•</span> <i class="calibre3">S. lugdunensis</i> is <i class="calibre3">virulent</i> and should be treated like <i class="calibre3">S. aureus</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><i class="calibre3">Enterococcus</i></p></td>
<td class="bg0-b"><p class="tab">Ampicillin + [CTX or gent]; VRE needs linezolid or dapto</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">GNRs</p></td>
<td class="bg0-b"><p class="tab">HACEK: CTX. <i class="calibre3">Pseudomonas</i>: 2 anti-Pseudomonal agents [eg, B-lactam + (AG or quinolone)]; consult ID.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Fungi</p></td>
<td class="bg0-b"><p class="tab">Liposomal ampho or micafungin. Risk factors: TPN, lines, pacemaker/ICD, prothesis, IVDU. <i class="calibre3">Ophtho consult for candidemia.</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg" colspan="2"><p class="tab"><b class="calibre4">Early surgical consult for any prosthetic valve infection regardless of organism</b></p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> De-escalate abx to organism-directed therapy once sensitivities return</p>
<p class="bl"><span class="sbl">•</span> Repeat BCx q24–48h until Pt defervesces and BCx ⊖</p>
<p class="bl"><span class="sbl">•</span> Anticoag. controversial; d/c for ≥2 wk if PVE and CNS embolic event. Can continue antiplatelet Rx if no CNS event in all comers, but no proven benefit to adding.</p>
<p class="bl"><span class="sbl">•</span> Monitor for complications of endocarditis (CHF, conduction block, new emboli, etc., which can occur even on abx) and of abx Rx (interstitial nephritis, ARF, neutropenia, etc.)</p>
<p class="bl"><span class="sbl">•</span> Duration of Rx: usually <b class="calibre4">4–6 wk</b></p>
<p class="bl1">After ≥10d IV abx, if doing well, and depending on organism, Pt, &amp; abx choices, may consider Δ’ing to PO in consultation with ID <span class="s1r">(<i class="calibre3">NEJM</i> 2019;380:415)</span></p>
<p class="bl1">Uncomplicated right-sided NVE or PCN-S strep spp → 2 wk may be comparable</p>
<p class="h2a">Indications for surgery <span class="s">(<i class="calibre3">EHJ</i> 2015;36:3075)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Severe valvular dysfunction</b> → <b class="calibre4">refractory CHF:</b> <i class="calibre3">emergent</i> if refractory cardiogenic shock (ie, despite ICU-level Rx); <i class="calibre3">urgent</i> (w/in days) if persistent refractory heart failure; <i class="calibre3">elective</i> (w/in wks) if asx severe AI or MR. Consult cardiac surgery early.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Uncontrolled infxn</b> (typically urgent surgery w/in days): periannular abscess (10–40% NVE, 60–100% PVE), heart block, fistula, worsening conduction, PVE w/ dehiscence, ↑ veg. size or persistent sepsis (eg, ⊕ BCx after ~1 wk of appropriate IV abx &amp; no drainable metastatic focus or other identifiable cause; complicated if due to septic emboli to lung)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Organism:</b> consider surgery for <i class="calibre3">S. aureus</i>, fungal or multiRx-resistant organisms</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Prosthetic valve:</b> dysfunction or dehiscence</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Systemic embolism</b> (20–50%): risk 4.8/1000 Pt days in 1st wk, 1.7/1000 thereafter. Urgent surgery if L-sided w/ &gt;10 mm veg &amp; severe AI/MR <span class="s1r">(<i class="calibre3">NEJM</i> 2012;366:2466)</span> or if recurrent emboli, embolism &amp; &gt;10 mm veg, or &gt;15 mm veg despite approp. abx.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cerebral emboli</b> no longer considered contraindic to surgery unless severe stroke or hemorrhage (then ideally wait 1 mo) <span class="s1r">(<i class="calibre3">Stroke</i> 2006;37:2094)</span></p>
<p class="h2a">Prognosis</p>
<p class="bl"><span class="sbl">•</span> NVE: non-IVDU <i class="calibre3">S. aureus</i> → 30–45% mortality; IVDU <i class="calibre3">S. aureus</i> (often right-sided) → 10–15% mortality; SBE → 10–15% mortality</p>
<p class="bl"><span class="sbl">•</span> PVE → 23% mortality</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre10"/>
<col class="calibre11"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabc"><b class="calibre4">Endocarditis Prophylaxis</b> <span class="tfont1">(<i class="calibre3">Circ</i> 2007;116:1736)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cardiac conditions</b><a id="st10" class="calibre1"></a><a href="part0011.html#sst10" class="calibre1">*</a></p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">Prosthetic valve; previous NVE; congenital heart disease</b> (CHD) including unrepaired or incompletely repaired cyanotic CHD (palliative shunts or conduits), 1<sup class="calibre35">st</sup> 6 mo after completely repaired CHD using prosthetic material; <b class="calibre4">cardiac transplant recipients w/ valvulopathy</b></p>
<p class="tabh">(Prophylaxis no longer rec. in acquired valvular dysfxn, bicuspid AoV, MVP with leaflet thickening or regurgitation, HCMP)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Procedures</b><a href="part0011.html#sst10" class="calibre1">*</a></p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">Dental:</b> manipulation of gingival tissue or periapical region of teeth or perf oral mucosa (eg, extraction, periodontal, implant, root canal, cleaning)</p>
<p class="tab"><b class="calibre4">Respiratory:</b> incision or biopsy of respiratory mucosa</p>
<p class="tabh">(no prophylaxis for GI or GU procedures)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Regimens</b></p></td>
<td class="bg"><p class="tab">Oral: <b class="calibre4">amoxicillin 2 g 30–60 min before</b></p>
<p class="tab">Unable to take PO: amp 2 g IM/IV or cefazolin or Cftx 1 g IM/IV</p>
<p class="tab">PCN-allergic: clinda 600 mg PO/IM/IV</p></td>
</tr>
</table>
<p class="tsr"><a id="sst10" class="calibre1"></a><a href="part0011.html#st10" class="calibre1">*</a>Pts should meet both indications (high-risk condition &amp; high-risk procedure) to qualify for Ppx</p>
<h2 class="ct"><a id="h89" class="calibre7"></a><a id="page_6-15" class="calibre7"></a><a href="part0002.html#rh98" class="calibre7">TUBERCULOSIS</a></h2>
<p class="h2a">Epidemiology</p>
<p class="bl"><span class="sbl">•</span> U.S.: 10–15 million infected (15× ↑ risk if foreign-born or minority); worldwide: ~2 billion</p>
<p class="bl"><span class="sbl">•</span> Multidrug-resistant (<b class="calibre4">MDR</b>) <b class="calibre4">TB:</b> resistant to INH &amp; rifampin. Can occur as 1° infxn.</p>
<p class="bl"><span class="sbl">•</span> Extensively drug-resistant <b class="calibre4">(XDR) TB</b> resistant to INH, RIF, FQ, and injectables</p>
<p class="bl"><span class="sbl">•</span> Risk factors <span class="s1r">(<i class="calibre3">NEJM</i> 2011;364:1441)</span></p>
<p class="bl1"><i class="calibre3">Acquisition:</i> immigrant from high-prevalence area, homeless, IVDU or medically underserved, resident or worker in jail or long-term facility, healthcare worker, close contact to Pt w/ active TB</p>
<p class="bl1"><i class="calibre3">Reactivation:</i> risk is 5% in first 2 yr, 5–10% over lifetime, but higher if HIV ⊕, immunosupp. incl. biologics, CKD (HD), uncontrolled DM, cancer, transplant, malnourished, underweight, smoker, IVDU, alcohol</p>
<p class="h2a">Microbiology &amp; natural history</p>
<p class="bl"><span class="sbl">•</span> Transmission of <i class="calibre3">Mycobacterium tuberculosis</i> via small-particle aerosols (droplet nuclei)</p>
<p class="bl"><span class="sbl">•</span> 90% of infected normal hosts will never develop clinically evident disease</p>
<p class="bl"><span class="sbl">•</span> Localized disease: healing &amp; calcification <i class="calibre3">or</i> progressive 1° TB (at site of infection)</p>
<p class="bl"><span class="sbl">•</span> Hematogenous spread: latent infection ± reactivation TB <i class="calibre3">or</i> progressive dissem. TB</p>
<p class="h2a">Screening for latent TB</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Whom to screen:</b> high-prevalence and high-risk populations (HIV ⊕ Pts should be tested as part of initial evaluation and annually thereafter)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">How to screen</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">IFN-γ release assays (IGRA):</b> Ag-stimulated IFN-γ release from patient’s T-cells. Preferred to PPD due to ↑ Sp in BCG vaccine Pts <span class="s1r">(<i class="calibre3">Annals</i> 2008;149:177)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Tuberculin skin test (TST or also known as PPD):</b> inject purified protein interdermally then examine for wheal 48–72 hrs later. Interpret based on max diameter of induration.</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tabheadc"><b class="calibre4">Size of Reaction</b></p></td>
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Persons considered to have</b> <span class="s2">⊕</span> <b class="calibre4">test</b> <span class="tfont1">(<i class="calibre3">NEJM</i> 2002;347:1860)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">&gt;<b class="calibre4">5 mm</b></p></td>
<td class="bg0-b"><p class="tab">HIV ⊕ or immunosupp (eg, prednisone 15 mg/d × &gt;1 mo)</p>
<p class="tab">Close contacts of Pt w/ active TB; CXR w/ apical fibrosis c/w TB</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">&gt;<b class="calibre4">10 mm</b></p></td>
<td class="bg0-b"><p class="tab">All other high-risk or high-prevalence populations</p>
<p class="tab">Recent conversion (↑ in induration by &gt;10 mm in last 2 y)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">&gt;<b class="calibre4">15 mm</b></p></td>
<td class="bg0-b"><p class="tab">Everyone else</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">False ⊖</p></td>
<td class="bg0-b"><p class="tab">Faulty application, anergy (including from active TB), acute TB</p>
<p class="tab">(2–10 wk to convert), acute non-TB mycobacteria (NTM), malignancy</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tabc">False ⊕</p></td>
<td class="bg0-b"><p class="tab">Improper reading, cross-reaction with NTM, BCG vaccination (although usually &lt;10 mm by adulthood)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tabc">Booster effect</p></td>
<td class="bg"><p class="tab">↑ induration b/c immunologic boost by prior skin test in prev sensitized individual (by TB, NTM or BCG). Test ⊖ → ⊕ but <i class="calibre3">not</i> true conversion due to <i class="calibre3">recent</i> infxn. 2<sup class="calibre35">nd</sup> test true baseline. Can be 1 y after initial test.</p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Neither screening test rules in/out active TB.</b> Use both IGRA &amp; PPD combined to ↑ Se (to 80–90%). Relies on host immune system, therefore limited Se in immunocompromised <span class="s1r">(<i class="calibre3">J Clin Epi</i> 2010;63:257; <i class="calibre3">CID</i> 2011;52:1031)</span>.</p>
<p class="h2a">Clinical manifestations <span class="s">(<i class="calibre3">Lancet</i> 2016;387:1211)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Primary TB pneumonia:</b> middle or lower lobe consolidation, ± effusion, ± cavitation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">TB pleurisy:</b> can occur w/ primary or reactivation. Due to breakdown of granuloma w/ spilling of contents into pleural cavity and local inflammation. <b class="calibre4">Pulmonary effusion</b> ± pericardial and peritoneal effusions (tuberculous polyserositis).</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Reactivation TB pulmonary disease:</b> apical infiltrate ± volume loss ± cavitation</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Miliary TB:</b> acute or insidious; due to hematogenous dissemination; usually in immunosupp, DM, EtOH, elderly or malnourished. <b class="calibre4">Constitutional sx</b> (fever, night sweats, weight loss) usually prominent. Pulm disease w/ millet seed-like lesions (2–4 mm) on CXR or chest CT (latter more Se) present in 60–80% of those w/ miliary TB.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Extrapulmonary TB:</b> lymphadenitis, pericarditis, peritonitis, meningitis, nephritis ± sterile pyuria, osteomyelitis (vertebral = Pott’s disease), hepatitis, splenitis, cutaneous, arthritis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">TB and HIV:</b> HIV ⊕ at ↑ risk infxn, progressive 1° infxn &amp; reactivation. Risk of progression from infxn to disease &gt;8–10%/y, higher risk with ↓ CD4. Reinfection (also w/ MDR) significant, esp. in hyperendemic areas.</p>
<p class="h2a">Diagnostic studies for active TB <span class="s">(<i class="calibre3">high index of suspicion is key!</i>)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">AFB smear</b> (rapid dx) and <b class="calibre4">culture</b> (↑ Se &amp; allows sensitivity testing) of sputum, BAL, pleura, etc.; <i class="calibre3">avoid FQ</i> if considering TB (can compromise dx yield)</p>
<p class="bl"><span class="sbl">•</span> Gene Xpert PCR (rapid dx) can also detect rifampin resistance; validated on nonbloody sputum only. Sp 98% &amp; Se 74% independent of HIV status <span class="s1r">(<i class="calibre3">AJRCCM</i> 2014;189;1426)</span>.</p>
<p class="bl"><span class="sbl">•</span> PCR: 94–97% Se c/w smear; 40–77% Se c/w culture <span class="s1r">(<i class="calibre3">JAMA</i> 2009;301:1014)</span></p>
<p class="bl"><a id="page_6-16" class="calibre1"></a><span class="sbl">•</span> CXR: classically fibrocavitary apical disease in reactivation vs. middle &amp; lower lobe consolidation in 1° TB but distinction imperfect. HIV ⊕ assoc. w/ nonapical disease regardless of timing <span class="s1r">(<i class="calibre3">JAMA</i> 2005;293:2740)</span>.</p>
<p class="bl"><span class="sbl">•</span> Adenosine deaminase testing: useful in extrapulmonary sites; best validated for ascites</p>
<p class="h2a">Treatment of latent TB</p>
<p class="bl"><span class="sbl">•</span> Treat Pts who are ⊕ based on guidelines or any exposed HIV ⊕ or immunocompromised Pt <span class="s1r">(<i class="calibre3">NEJM</i> 2015;372:2127; <i class="calibre3">Eur Respir J</i> 2015;46:1563)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">R/o active disease</b> in any Pt w/ suggestive s/s before starting INH (cough, fever, nightsweats), CXR (though may be nl in immunosupp.)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre51"/>
<col class="calibre52"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Scenario</b></p></td>
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Prophylaxis Regimen</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">PPD/IGRA ⊕ (regardless of HIV status), or contact case INH resistant</p></td>
<td class="bg0-b"><p class="tabh">1<sup class="calibre35">st</sup> line: Rifampin × 4 mo (non-inferior to INH, greater adherence and lower hepatotoxicity) <span class="tfont">(</span><span class="tfont"><i class="calibre3">NEJM</i></span> <span class="tfont">20</span><span class="tfont">1</span><span class="tfont">8;5:440)</span>.</p>
<p class="tabh"><i class="calibre3">Alternative:</i> [INH 5 mg/kg + vitamin B6 × 9 mo] <i class="calibre3">or</i> [INH + Rifapentine weekly × 12 wk]</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Contact case known or suspected to have MDR TB</p></td>
<td class="bg"><p class="tab">No proven regimen: ? PZA + EMB, ? PZA + FQ</p></td>
</tr>
</table>
<p class="tsr">(INH, isoniazid; RIF, rifampin; PZA, pyrazinamide; EMB, ethambutol; FQ, fluoroquinolone)</p>
<p class="bl"><span class="sbl">•</span> ✔ LFTs monthly if receiving INH (risk ↑ w/ age; <i class="calibre3">Chest</i> 2005;128:116): if 5× ULN <i class="calibre3">or</i> sx → stop TB meds &amp; re-eval</p>
<p class="h2a"><b class="calibre4">Patient isolation</b></p>
<p class="bl"><span class="sbl">•</span> Decision based on likelihood. Consider when cough, dyspnea, hemoptysis + 1 risk factor (HIV ⊕, foreign born, substance use disorder, homeless, recent incarceration, prior TB or exposure).</p>
<p class="bl"><span class="sbl">•</span> Discontinue if alternative dx, AFB smear neg ×3, or TB treated for 2 wk &amp; AFB neg</p>
<p class="h2a">Treatment of active tuberculosis <span class="s">(<i class="calibre3">NEJM</i> 2015;373:2149; <i class="calibre3">Lancet</i> 2016;387:1211)</span></p>
<p class="bl"><span class="sbl">•</span> Treatment requires several drugs to prevent resistance (see below)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Suspect MDR TB</b> if prior TB Rx, travel to area w/ ↑ rates of MDR (India, China, Russia, South Africa), exposure to person w/ likely MDR-TB, poor Rx adherence, INH resis. in community ≥4% (includes most of U.S.), extrapulm. TB, HIV ⊕ <span class="s1r">(<i class="calibre3">NEJM</i> 2008;359:636)</span></p>
<p class="bl"><span class="sbl">•</span> Screen for HIV. If ⊕ → consult ID re: timing of concurrent HIV Rx</p>
<p class="bl"><span class="sbl">•</span> “Paradoxical <i class="calibre3">worsening</i>” of sx can occur after starting Rx. More common w/ extrapulm TB &amp; more frequent/severe w/ concurrent immune reconstitution (eg, HIV ⊕ Pts started on ARVs, Pts taken off immunosuppression). <i class="calibre3">Must r/o Rx failure</i> (repeat Cx, imaging, etc.).</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre16"/>
<col class="calibre29"/>
<col class="calibre36"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">Antituberculous Medications</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Drug</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Dose</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Adverse Effects<a id="st11" class="calibre1"></a><a href="part0011.html#sst11" class="calibre1">*</a></b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Isoniazid (INH)</p></td>
<td class="bg0-br"><p class="tab">300 mg PO qd</p></td>
<td class="bg0-b"><p class="tab">Hepatitis, periph neuropathy (↓ risk by suppl. vit B<sub class="calibre13">6</sub>), drug-induced lupus</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Rifampin (RIF)</p></td>
<td class="bg0-br"><p class="tab">600 mg PO qd</p></td>
<td class="bg0-b"><p class="tab">Orange tint of body fluids, GI upset, hepatitis, hypersensitivity, fever, drug interactions, avoid EtOH</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Pyrazinamide (PZA)</p></td>
<td class="bg0-br"><p class="tab">25 mg/kg PO qd</p></td>
<td class="bg0-b"><p class="tab">Hepatitis, hyperuricemia, arthritis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Ethambutol (EMB)</p></td>
<td class="bg0-br"><p class="tab">15–25 mg/kg PO qd</p></td>
<td class="bg0-b"><p class="tab">Optic neuritis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Streptomycin (SM)</p></td>
<td class="bg0-br"><p class="tab">15 mg/kg IM qd</p></td>
<td class="bg0-b"><p class="tab">Ototoxicity, nephrotoxicity</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Amikacin (AMK)</p></td>
<td class="bg0-br"><p class="tab">15 mg/kg IM qd</p></td>
<td class="bg0-b"><p class="tab">Ototoxicity, nephrotoxicity</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Quinolone (moxifloxacin)</p></td>
<td class="bg0-r"><p class="tab">400 mg PO qd</p></td>
<td class="bg"><p class="tab">GI upset, tendinopathy, ↑ QTc</p></td>
</tr>
</table>
<p class="tsr"><a id="sst11" class="calibre1"></a><a href="part0011.html#st11" class="calibre1">*</a>Risk of hepatitis ↑ w/ pre-existing liver disease. Consult ID if mod to severe liver disease, and consider holding/replacing PZA or INH.</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre17"/>
<col class="calibre24"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Scenario</b></p></td>
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Antituberculous Treatment Regimens</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Pulmonary TB</b></p>
<p class="tab"><b class="calibre4">≥4% INH-resist. in community</b> (includes most of U.S.)</p></td>
<td class="bg0-b"><p class="tab">INH + RIF + PZA + (EMB) until suscept. known</p>
<p class="tabh">If <i class="calibre3">sensitive</i> to INH &amp; RIF → INH + RIF + PZA × 2 mo, <i class="calibre3">then</i> → INH + RIF × 4 mo</p>
<p class="tab">If <i class="calibre3">resistant</i>, see next row</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Drug-resistant TB</b> (INH-R, RIF-R or MDR/XDR)</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Consult ID specialist</i></p>
<p class="tab"><span class="tfont">(</span><span class="tfont"><i class="calibre3">NEJM</i></span> <span class="tfont">2008;359:636)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Extrapulmonary TB</b></p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Consult ID specialist</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">TB in HIV</b> ⊕ <b class="calibre4">patient</b></p></td>
<td class="bg"><p class="tab"><i class="calibre3">Consult ID specialist</i></p></td>
</tr>
</table>
<p class="tsr">Individualize duration based on host, disease form, and rate of clinical/microbiologic improvement</p>
<h2 class="ct"><a id="h90" class="calibre7"></a><a id="page_6-17" class="calibre7"></a><a href="part0002.html#rh99" class="calibre7">HIV/AIDS</a></h2>
<p class="h2a">Definition &amp; Clinical Manifestations</p>
<p class="bl"><span class="sbl">•</span> Acute HIV: mono-like syndrome → rash, lymphadenopathy, fever, oral ulcers, pharyngitis, myalgias, diarrhea. Presents ~2–6 wk after infxn.</p>
<p class="bl"><span class="sbl">•</span> AIDS: HIV + CD4 &lt;200/mm<sup class="calibre15">3</sup> <i class="calibre3">or</i> AIDS-defining opportunistic infection (OI) or malignancy</p>
<p class="h2a">Epidemiology</p>
<p class="bl"><span class="sbl">•</span> ~1 million Americans living w/ HIV (1 in 8 unaware); ~36 million worldwide</p>
<p class="bl"><span class="sbl">•</span> Highest at risk are men who have sex with men (MSM) and African Americans</p>
<p class="bl"><span class="sbl">•</span> Routes: sexual (risk is 0.1–1% per sex act w/o ARV), IVDU, transfusions, needlesticks (0.3%), vertical (15–40% w/o ARV)</p>
<p class="h2a">Prophylaxis <span class="s">(<i class="calibre3">NEJM</i> 2015;373:2237; <i class="calibre3">Lancet</i> 2016;387:53; <i class="calibre3">J Infect Dis</i> 2018;218:16)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Preexposure</b> (PrEP): TDF/FTC qd effective &amp; safe in high-risk, adherent populations. Use in heterosexuals or MSM w/: (1) serodiscordant partner, (2) inconsistent condom use, or (3) STI w/in 6 mo; or IVDU w/ equipment sharing or high-risk for HIV <span class="s1r">(<i class="calibre3">JAMA</i> 2019;321:2203)</span>. On-demand PrEP effective option for MSM (44–86% ↓). ✔ renal fxn, STIs, &amp; HIV q3 mo.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Postexposure</b> (PEP): present &lt;72 hr after high-risk exposure from HIV+ source (case-by-case decision if HIV status unknown). Test baseline HIV, STIs, HBV, HCV. Rx: 2 NRTIs (usually TDF/FTC) + RAL or DTG × 4 wk. Consider initiating PrEP.</p>
<p class="bl"><span class="sbl">•</span> Treatment is prevention: early Rx of HIV ⊕ Pt prevents transmission to partners <span class="s1r">(<i class="calibre3">NEJM</i> 2016;375:830)</span>. Risk of transmission w/ unprotected sex w/ undetectable viral load is ~0% <span class="s1r">(<i class="calibre3">JAMA</i> 2016;316:171; <i class="calibre3">Lancet HIV</i> 2018;5:e438)</span>.</p>
<p class="h2a">Screening and Diagnosis</p>
<p class="bl"><span class="sbl">•</span> Screen all ages 13–64 once in lifetime &amp; every pregnancy. High risk (IVDU, sex workers, MSM &gt;1 partner) screen annually <span class="s1r">(<i class="calibre3">JAMA</i> 2018;320:379)</span>.</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">HIV Ab/p24Ag</b> (ELISA assay): ⊕ 1–12 wk after acute infxn; &gt;99% Se; 1° screening test</p>
<p class="bl"><span class="sbl">•</span> If ⊕, Ab differentiation assay confirms and differentiates HIV-1 vs. -2 <span class="s1r">(<i class="calibre3">MMWR</i> 2013;62:489)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">HIV RNA PCR viral load</b> in plasma; assay range is 20–10 million copies/mL; ~2% false ⊕, but usually low # copies; in contrast, should be very high (&gt;750 k) in 1° infxn</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CD4 count:</b> not a dx test, b/c can be HIV ⊕ w/ normal CD4 or be HIV ⊖ w/ low CD4</p>
<p class="h2a">Approach to newly diagnosed HIV ⊕ Pt <span class="s">(<i class="calibre3">JAMA</i> 2018;320:379)</span></p>
<p class="bl"><span class="sbl">•</span> Document HIV infection; counsel re: treatment options, adherence, &amp; disclosure</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Lab evaluation:</b> CD4 count, HIV VL &amp; genotype, CBC w/ diff., Cr, lytes, LFTs, A1c, &amp; fasting lipids; PPD or IGRA, toxo, syphilis, <i class="calibre3">Chlamydia</i> &amp; gonorrhea screens, Hep A/B/C serologies; G6PD (if PCP ppx), Pap smear/anal pap in ♀/♂; ± CMV IgG, baseline CXR</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Initiate ARV early</b> (same day prior to labs/genotype and w/ <i class="calibre3">guidance from HIV specialist</i>) regardless of CD4 level because ↓ mortality <span class="s1r">(<i class="calibre3">NEJM</i> 2015;373:795)</span></p>
<p class="bl"><span class="sbl">•</span> Regimens include: 2 NRTI (eg, TAF + FTC) + <i class="calibre3">either</i> int. inhib or boosted PI (eg, DRV/r)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre61"/>
<col class="calibre16"/>
<col class="calibre64"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tab"><b class="calibre4">Common Antiretrovirals (ARVs)</b></p></td>
<td class="bg1-b"><p class="tab"><b class="calibre4">Common Side Effects</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabc"><b class="calibre4">NRTI</b></p></td>
<td class="bg0-br"><p class="tab">abacavir (ABC; Ziagen)</p>
<p class="tab">emtricitabine (FTC; Emtriva)</p>
<p class="tab">lamivudine (3TC; Epivir)</p>
<p class="tab">tenofovir (TAF or TDF)</p>
<p class="tab">zidovudine (AZT; Retrovir)</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Class:</i> GI intol, lipoatrophy, lactic acidosis</p>
<p class="tab">ABC: hypersensitivity (3%), ✔ <b class="calibre4">HLA-B<a id="st12" class="calibre1"></a><a href="part0011.html#sst12" class="calibre1">*</a>5701</b></p>
<p class="tab">AZT: BM suppression (esp. macrocytic anemia)</p>
<p class="tab">TDF: renal toxicity</p>
<p class="tab">TAF: minimal renal toxicity</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabc"><b class="calibre4">NNRTI</b></p></td>
<td class="bg0-br"><p class="tab">efavirenz (EFV; Sustiva)</p>
<p class="tab">etravirine (ETR; Intelence)</p>
<p class="tab">nevirapine (NVP; Viramune)</p>
<p class="tab">rilpivirine (RPV; Edurant)</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Class:</i> rash, hepatitis, mixed CYP450 inducer/inhib</p>
<p class="tab">EFV: CNS effects (incl depression)</p>
<p class="tabh">NVP: rash and hypersensitivity [risk factors are female, CD4 &gt;250, pregnancy (∴ avoid)]</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabc"><b class="calibre4">PI</b></p></td>
<td class="bg0-br"><p class="tab">atazanavir (ATV; Reyataz)</p>
<p class="tab">darunavir (DRV; Prezista)</p>
<p class="tab">lopinavir/riton. (LPV/r; Kaletra)</p>
<p class="tab">ritonavir (RTV; Norvir)</p></td>
<td class="bg0-b"><p class="tabh"><i class="calibre3">Class:</i> GI intol; hepatotoxicity; inhibit CYP450 (caution w/ statins); T2DM; truncal obesity; hyperlipid (less w/ ATV); MI <span class="tfont">(</span><span class="tfont"><i class="calibre3">NEJM</i></span> <span class="tfont">2007;356:</span><span class="tfont">1</span><span class="tfont">723)</span></p>
<p class="tab">ATV: crystalluria → nephrolithiasis</p>
<p class="tab">DRV: rash (<b class="calibre4">1</b>0%); possible sulfa cross-reactivity</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabc"><b class="calibre4">FI</b></p></td>
<td class="bg0-br"><p class="tab">enfuvirtide (T20; Fuzeon)</p></td>
<td class="bg0-b"><p class="tab">Injection site reaction</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabc"><b class="calibre4">EI</b></p></td>
<td class="bg0-br"><p class="tab">maraviroc (MVC; Selzentry)</p></td>
<td class="bg0-b"><p class="tab">Dizziness, hepatotoxicity; ✔ CCR5 tropism assay</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabc"><b class="calibre4">II</b></p></td>
<td class="bg0-br"><p class="tab">bictegravir (BIC; Biktarvy) dolutegravir (DTG; Tivicay)</p>
<p class="tab">elvitegravir (EVG; Vitekta)</p>
<p class="tab">raltegravir (RAL; Isentress)</p></td>
<td class="bg0-b"><p class="tab">Class: diarrhea &amp; other GI intol; ↑ CPK</p>
<p class="tab">DTG ↑ metformin levels; monitor glc</p>
<p class="tab">DTG a/w neural tube defects</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r1"><p class="tabc"><b class="calibre4">B<a href="part0011.html#sst12" class="calibre1">*</a></b></p></td>
<td class="bg0-r"><p class="tab">ritonavir (r); cobicistat (COBI)</p></td>
<td class="bg"><p class="tab">Drug interactions (inhibit CYP450)</p></td>
</tr>
</table>
<p class="tsr">NRTI, nucleoside/tide reverse transcriptase inhibitor; NNRTI, nonnucleoside RTI; PI, protease inhibitor; FI, fusion inhibitor; EI, entry inhibitor (CCR5 antagonist); II, integrase inhibitor; <a id="sst12" class="calibre1"></a><a href="part0011.html#st12" class="calibre1">*</a>booster to give w/ other ARVs; several multiclass combination pills exist</p>
<p class="bl"><a id="page_6-18" class="calibre1"></a><span class="sbl">•</span> Initiation of ARVs may <i class="calibre3">transiently worsen</i> existing OIs (TB, MAC, CMV, others) due to immune reconstitution inflammatory syndrome (IRIS). Prednisone during 1<sup class="calibre15">st</sup> 4 wk of ARVs ↓ risk for TB-associated IRIS <span class="s1r">(<i class="calibre3">NEJM</i> 2018;379:1915)</span>.</p>
<p class="h2a">Approach to previously established HIV ⊕ Pt</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">H&amp;P</b> (mucocutaneous, neurocognitive, OIs, malignancies, STDs); meds</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Review ARVs</b> (past and current); if any must be interrupted, <i class="calibre3">stop all</i> to ↓ risk of resistance</p>
<p class="bl"><span class="sbl">•</span> Failing regimen = unable to achieve undetectable viral load, ↑ viral load, ↓ CD4 count or clinical deterioration (with detectable viral load consider genotypic or phenotypic assay)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre41"/>
<col class="calibre16"/>
<col class="calibre43"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="3"><p class="tabheadc"><b class="calibre4">OI Prophylaxis</b> <span class="tfont1">(<a href="https://aidsinfo.nih.gov/guidelines" class="calibre1">https://aidsinfo.nih.gov/guidelines</a> &amp; <i class="calibre3">JAMA</i> 2018;320:379)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">OI</b></p></td>
<td class="bg0-br"><p class="tab"><b class="calibre4">Indication</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">1° Prophylaxis</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Tuberculosis</b></p></td>
<td class="bg0-br"><p class="tab">⊕ PPD (≥5 mm)/IGRA <i class="calibre3">or</i> high-risk exposure</p></td>
<td class="bg0-b"><p class="tab">Rifampin × 4 mo (noninferior to INH, but ✔ for drug interactions) <i class="calibre3">or</i> INH + vit B<sub class="calibre13">6</sub> × 9 mo</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4"><i class="calibre3">Pneumocystis</i> <i class="calibre3">jiroveci</i> (PCP)</b></p></td>
<td class="bg0-br"><p class="tab">CD4 &lt;200/mm<sup class="calibre35">3</sup> <i class="calibre3">or</i> CD4 &lt;14% <i class="calibre3">or</i> thrush</p></td>
<td class="bg0-b"><p class="tab">TMP-SMX DS or SS qd or DS tiw <i class="calibre3">or</i> dapsone 100 mg qd <i class="calibre3">or</i> atovaquone 1500 mg qd <i class="calibre3">or</i> pentamidine 300 mg inh q4wk</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Toxoplasmosis</b></p></td>
<td class="bg0-br"><p class="tab">CD4 &lt;100/mm<sup class="calibre35">3</sup> <i class="calibre3">and</i> ⊕ <i class="calibre3">Toxo</i> IgG</p></td>
<td class="bg0-b"><p class="tab">TMP-SMX DS qd <i class="calibre3">or</i> dapsone 50 mg qd + pyrimeth. 50 mg qwk + leucovorin 25 qwk</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">MAC</b></p></td>
<td class="bg0-b" colspan="2"><p class="tab">Ppx no longer rec. if effective ART initiated</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-b" colspan="3"><p class="tab">Stop 1° prophylaxis if CD4 &gt;initiation threshold &gt;3–6 mo on ARVs</p></td>
</tr>
<tr class="calibre12">
<td class="bg" colspan="3"><p class="tab">Stop 2° prophylaxis (maintenance therapy for prior OI; drugs and doses differ by OI) if clinical resolution or stabilization and CD4 thresholds have been exceeded × 3–6 mo</p></td>
</tr>
</table>
<p class="h">C<small class="calibre30">OMPLICATIONS</small> <small class="calibre30">OF</small> HIV/AIDS</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tabhead"><b class="calibre4">CD4 Count</b></p></td>
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Complications</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Any CD4 count</b></p></td>
<td class="bg0-b"><p class="tab">Influenza, HAV, HBV, HPV, VZV, <i class="calibre3">S. pneumo</i>, TB</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">&lt;<b class="calibre4">500</b></p></td>
<td class="bg0-b"><p class="tab">Constitutional sx; noninfectious disease (CVD, bone, oncologic)</p>
<p class="tabh">Mucocutaneous: Kaposi’s sarcoma; seborrheic dermatitis; oral hairy leukoplakia; lymphoma; candidiasis; HSV</p>
<p class="tab">Recurrent bacterial infections, TB (pulm and extrapulm); neurosyphilis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">&lt;<b class="calibre4">200</b></p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">PCP, Toxo, Bartonella, Crypto, Histo</i> (if endemic), <i class="calibre3">Coccidio</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">&lt;<b class="calibre4">50–100</b></p></td>
<td class="bg"><p class="tab">CMV, MAC, CNS lymphoma, PML, death (&lt;50 is medical emergency)</p>
<p class="tab">Invasive aspergillosis, bacillary angiomatosis (dissem. <i class="calibre3">Bartonella</i>)</p></td>
</tr>
</table>
<p class="h2a">Fever</p>
<p class="bl"><span class="sbl">•</span> Etiologies <span class="s1r">(<i class="calibre3">Infect Dis Clin North Am</i> 2007;21:1013)</span></p>
<p class="bl1"><b class="calibre4">infxn (82–90%): MAC</b>, <b class="calibre4">TB</b>, <b class="calibre4">CMV</b>, <b class="calibre4">early PCP</b>, <i class="calibre3">Histo</i>, <i class="calibre3">Crypto</i>, <i class="calibre3">Coccidio</i>, <i class="calibre3">Toxo</i>, endocarditis</p>
<p class="bl1"><b class="calibre4">noninfectious: lymphoma</b>, <b class="calibre4">drug reaction.</b> Non 1° HIV itself rarely (&lt;5%) cause of fever.</p>
<p class="bl"><span class="sbl">•</span> Workup: guided by CD4 count, s/s, epi, &amp; exposures</p>
<p class="bl1">CBC, chem, LFTs, BCx, CXR, UA, mycobact. &amp; fungal cx, ✔ meds, ? ✔ chest &amp; abd CT</p>
<p class="bl1">CD4 &lt;100–200 → serum crypto Ag, LP, urinary <i class="calibre3">Histo</i> Ag, CMV PCR</p>
<p class="bl1">pulmonary s/s → CXR; ABG; sputum for bacterial cx, PCP, AFB; bronchoscopy</p>
<p class="bl1">diarrhea → stool cx, O&amp;P, AFB; direct visualization with bx on colonoscopy</p>
<p class="bl1">cytopenias → BM bx for, path &amp; cx of aspirate including for mycobacteria &amp; fungi</p>
<p class="h2a">Cutaneous</p>
<p class="bl"><span class="sbl">•</span> Seborrheic dermatitis; eosinophilic folliculitis; <b class="calibre4">warts</b> (HPV); HSV &amp; VZV; MRSA skin &amp; soft tissue infxns; scabies; candidiasis; eczema; prurigo nodularis; psoriasis; drug eruption; subungual onychomycosis (at nail bed)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Molluscum contagiosum</b> (poxvirus): 2–5 mm pearly papules w/ central umbilication</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Kaposi’s sarcoma</b> (KSHV or HHV8): red-purple nonblanching nodular lesions</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Bacillary angiomatosis</b> (disseminated <i class="calibre3">Bartonella</i>): friable violaceous vascular papules</p>
<p class="h2a">Ophthalmologic</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CMV retinitis</b> (CD4 usu &lt;50); Rx: gan- or valganciclovir, ganciclovir implant or cidofovir</p>
<p class="bl"><span class="sbl">•</span> HZV, VZV, <b class="calibre4">syphilis</b> (any CD4 count, <i class="calibre3">treat as neurosyphilis</i>) or <i class="calibre3">Toxo:</i> CD4 usually &lt;100</p>
<p class="h2a">Oral</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Aphthous ulcers; KS; thrush</b> (oral candidiasis): curd-like patches typically w/ burning or pain; <b class="calibre4">oral hairy leukoplakia:</b> painless proliferation of papillae w/ adherent white coating usually on lateral tongue, caused by EBV but not precancerous</p>
<p class="h2a">Endocrine/metabolic</p>
<p class="bl"><span class="sbl">•</span> Hypogonadism<b class="calibre4">;</b> adrenal insufficiency (CMV, MAC, TB, HIV or med-related); wasting <b class="calibre4">osteopenia/porosis</b> (at all CD4 counts); <b class="calibre4">fragility fractures</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Lipodystrophy:</b> central obesity, peripheral lipoatrophy, dyslipidemia, hyperglycemia</p>
<p class="h2a"><a id="page_6-19" class="calibre1"></a>Cardiovascular <span class="s">(<i class="calibre3">JACC</i> 2013;61:511)</span></p>
<p class="bl"><span class="sbl">•</span> CAD (HIV incr risk indep of classic risk fx); dilated CMP; pulm HTN; pericarditis/effusion</p>
<p class="bl"><span class="sbl">•</span> Higher rates of VTE, stroke, worse outcomes after MI <span class="s1r">(<i class="calibre3">JAIDS</i> 2012;60:351; <i class="calibre3">Circ</i> 2013;127:1767)</span></p>
<p class="h2a">Pulmonary</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre17"/>
<col class="calibre24"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Radiographic Pattern</b></p></td>
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Common Causes</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Normal</b></p></td>
<td class="bg0-b"><p class="tab">Early PCP</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Diffuse interstitial infiltrates</b></p></td>
<td class="bg0-b"><p class="tab">PCP, TB, viral, or disseminated fungal</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Focal consolidation or masses</b></p></td>
<td class="bg0-b"><p class="tab">Bacterial or fungal, TB, KS</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Cavitary lesions</b></p></td>
<td class="bg0-b"><p class="tab">TB, non-TB mycobacteria, aspergillus, other fungal, bacterial (incl MRSA, <i class="calibre3">Nocardia, Rhodococcus</i>)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Pleural effusion</b></p></td>
<td class="bg"><p class="tab">TB, bacterial or fungal, KS, lymphoma</p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> <b class="calibre4"><i class="calibre3">Pneumocystis jiroveci</i> (PCP) pneumonia (CD4</b> &lt;<b class="calibre4">200)</b> <span class="s1r">(<i class="calibre3">NEJM</i> 1990;323:1444)</span></p>
<p class="bl1">constitutional sx, fever, night sweats, dyspnea on exertion, nonproductive cough</p>
<p class="bl1">CXR w/ interstitial pattern, ↓ P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub>, ↑ A-a ∇, ↑ LDH, ⊕ PCP sputum stain, ⊕ β-glucan</p>
<p class="bl1">Rx if P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> &gt;70: <b class="calibre4">TMP-SMX</b> 15–20 mg of TMP/kg divided tid, avg dose = DS 2 tabs PO tid</p>
<p class="bl1">Rx if P<sub class="calibre8">a</sub>O<sub class="calibre8">2</sub> &lt;70 or A-a gradient &gt;35: <b class="calibre4">prednisone</b> before abx (40 mg PO bid; ↓ after 5 d)</p>
<p class="bl1">HIV smokers are much more likely to die from lung cancer than OI <span class="s1r">(<i class="calibre3">JAMA</i> 2017;177:1613)</span></p>
<p class="h2a">Gastrointestinal &amp; hepatobiliary</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Esophagitis:</b> <i class="calibre3">Candida</i>, CMV (solitary, lg serpiginous), HSV (multiple, small shallow), aphthous ulcers, pills; EGD if no thrush or no response to empiric antifungals</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Enterocolitis:</b> <i class="calibre3">bacterial</i> (esp. if acute: shigella, salmonella, <i class="calibre3">C. diff</i>); <i class="calibre3">protozoal</i> (esp. if chronic: Giardia, Entamoeba, etc.); <i class="calibre3">viral</i> (CMV, adeno); <i class="calibre3">fungal</i> (histo); MAC; AIDS enteropathy; TB enteritis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">GI bleeding:</b> CMV, KS, lymphoma, histo; <b class="calibre4">proctitis:</b> HSV, CMV, <i class="calibre3">LGV, N. gonorrhoeae</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Hepatitis:</b> HBV, HCV, CMV, MAC, TB, histo, drug-induced</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">AIDS cholangiopathy:</b> often a/w CMV or <i class="calibre3">Cryptosporidium or Microsporidium</i> (at ↓ CD4)</p>
<p class="h2a">Renal</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">HIV-assoc.</b> nephropathy (collapsing FSGS); nephrotoxic drugs (eg, TDF → prox tub dysfxn)</p>
<p class="h2a">Hematologic/oncologic <span class="s">(<i class="calibre3">NEJM</i> 2018;378:1029)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Anemia:</b> ACD, BM infiltration by infxn or tumor, drug toxicity, hemolysis</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Leukopenia; thrombocytopenia</b> (bone marrow involvement, ITP); infection, ↑ <b class="calibre4">globulin</b></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Non-Hodgkin lymphoma:</b> ↑ frequency with any CD4 count, but incidence ↑ with ↓ CD4</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">CNS lymphoma:</b> CD4 count &lt;50, EBV-associated</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Kaposi’s sarcoma</b> (HHV-8): at any CD4 count, incidence ↑ b/c CD4 ↓, usu. MSM</p>
<p class="bl1"><i class="calibre3">Mucocut.</i> (violacious lesions); <i class="calibre3">pulmonary</i> (nodules, infiltrates, LAN); <i class="calibre3">GI</i> (bleed, obstruct.)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Cervical/anal CA</b> (HPV high risk in MSM); ↑ rates of liver (a/w HBV/HCV), gastric</p>
<p class="h2a">Neurologic</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Meningitis</b> <i class="calibre3">Crypto</i> (dx w/ CSF; serum CrAg 90% Se), bact (inc. <i class="calibre3">Listeria</i>), viral (HSV, CMV, 1° HIV), TB, histo, <i class="calibre3">Coccidio</i>, lymphoma; <b class="calibre4">neurosyphilis</b> (cranial nerve palsies)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Space-occupying lesions:</b> may present as HA, focal deficits or Δ MS. Workup: MRI, brain bx if suspect non-<i class="calibre3">Toxo</i> etiology <span class="s1r">(<i class="calibre3">Toxo</i> sero ⊖)</span> or no response to 2 wk of empiric anti-<i class="calibre3">Toxo</i> Rx (if <i class="calibre3">Toxo</i>, 50% respond by d3, 91% by d14; <i class="calibre3">NEJM</i> <span class="s">1993;329:995</span>)</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre39"/>
<col class="calibre60"/>
<col class="calibre60"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Etiology</b></p></td>
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Imaging Appearance</b></p></td>
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Diagnostic Studies</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Toxoplasmosis</b></p></td>
<td class="bg0-br"><p class="tab">Enhancing lesions, typically in basal ganglia (can be multiple)</p></td>
<td class="bg0-b"><p class="tab">⊕ <i class="calibre3">Toxo</i> serology (Se ~85%)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">CNS lymphoma</b></p></td>
<td class="bg0-br"><p class="tab">Enhancing ring lesion (single 60% of the time)</p></td>
<td class="bg0-b"><p class="tab">⊕ CSF PCR for EBV</p>
<p class="tab">⊕ SPECT or PET scan</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Progressive multifocal leukoencephalopathy (PML)</b></p></td>
<td class="bg0-br"><p class="tab">Multiple nonenhancing lesions in white matter</p></td>
<td class="bg0-b"><p class="tab">⊕ CSF PCR for JC virus</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Other:</b> abscess, nocardiosis, crypto, TB, CMV, HIV</p></td>
<td class="bg0-r"><p class="tab">Variable</p></td>
<td class="bg"><p class="tab">Biopsy</p></td>
</tr>
</table>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">AIDS dementia complex:</b> memory loss, gait disorder, spasticity (usually at CD4 ↓)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Depression:</b> ↑ rates of suicide/depression</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Myelopathy: infxn</b> (CMV, HSV), <b class="calibre4">cord compression</b> (epidural abscess, lymphoma)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Peripheral neuropathy:</b> meds, HIV, CMV, demyelinating</p>
<p class="h2a">Disseminated <i class="calibre3">Mycobacterium avium</i> complex (DMAC)</p>
<p class="bl"><span class="sbl">•</span> Fever, night sweats, wt loss, HSM, diarrhea, pancytopenia. Enteritis and mesenteric lymphadenitis if CD4 &lt;150, bacillemia if &lt;50. Rx: clarithro/azithro + ethambutol ± rifabutin.</p>
<p class="h2a">Cytomegalovirus (CMV)</p>
<p class="bl"><span class="sbl">•</span> Usually reactivation with ↓ CD4. Retinitis, esophagitis, colitis, hepatitis, neuropathies, encephalitis. CMV VL may be ⊖. Rx: ganciclovir, valganciclovir, foscarnet or cidofovir.</p>
<h2 class="ct"><a id="h91" class="calibre7"></a><a id="page_6-20" class="calibre7"></a><a href="part0002.html#rh100" class="calibre7">TICK-BORNE DISEASES</a></h2>
<p class="imagef"><img src="../images/00110.jpeg" alt="" class="calibre2"/></p>
<p class="fn">–: &lt;15%, +: 15–25%, ++: 25–50%, +++: 50–75%, ++++: &gt;75%</p>
<p class="h">L<small class="calibre30">YME</small> D<small class="calibre30">ISEASE</small></p>
<p class="h2a">Microbiology</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Spirochete</b> <i class="calibre3">B. burgdorferi</i> (consider coinfection w/ <i class="calibre3">Anaplasma, Babesia, B. miyamotoi</i>)</p>
<p class="bl"><span class="sbl">•</span> Transmitted by <b class="calibre4">ticks</b> (<i class="calibre3">Ixodes</i>, deer tick); infxn usually requires <b class="calibre4">tick attached</b> &gt;<b class="calibre4">36–48 h</b></p>
<p class="h2a">Epidemiology</p>
<p class="bl"><span class="sbl">•</span> Most common vector-borne illness in U.S.; peak incidence in summer (May–Aug)</p>
<p class="bl"><span class="sbl">•</span> Majority of cases in MN, WI, New England, northern mid-Atlantic, northern CA</p>
<p class="bl"><span class="sbl">•</span> Humans contact ticks usually in fields with low brush near wooded areas</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b" colspan="2"><p class="tabheadc"><b class="calibre4">Clinical Manifestations</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabc"><b class="calibre4">Stage</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Manifestations</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabc"><b class="calibre4">Stage 1 (early localized)</b> 3–30 d after bite</p></td>
<td class="bg0-b"><p class="tab">Pathogenesis: local effects of spirochete. <i class="calibre3">General:</i> <b class="calibre4">flu-like illness</b></p>
<p class="tabh"><i class="calibre3">Derm</i> (~80%): <b class="calibre4">erythema migrans</b> (EM) = erythematous patches w/ central clearing, ~6–38 cm in size &amp; often not “annular”</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br2"><p class="tabc"><b class="calibre4">Stage 2 (early dissem.)</b> wks to mos after bite</p></td>
<td class="bg0-b"><p class="tab">Pathogenesis: spirochetemia and immune response</p>
<p class="tab"><i class="calibre3">General:</i> fatigue, malaise, LAN, HA; fever uncommon</p>
<p class="tab"><i class="calibre3">Derm:</i> <b class="calibre4">multiple (1–100) annular lesions ≈ EM</b></p>
<p class="tab"><i class="calibre3">Rheum</i> (~10%): <b class="calibre4">migratory arthralgias</b> (knee &amp; hip) <b class="calibre4">&amp; myalgias</b></p>
<p class="tabh"><i class="calibre3">Neurologic</i> (~15%): cranial neuropathies (esp. <b class="calibre4">CN VII</b>), aseptic meningitis, mononeuritis multiplex (± pain), transverse myelitis</p>
<p class="tab"><i class="calibre3">Cardiac</i> (~8%): <b class="calibre4">conduction block</b>, myopericarditis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r1"><p class="tabc"><b class="calibre4">Stage 3 (late persistent)</b> mos to yrs after bite</p></td>
<td class="bg"><p class="tab">Pathogenesis: immune response</p>
<p class="tab"><i class="calibre3">Derm</i> (rare in U.S.)<i class="calibre3">:</i> acrodermatitis chronica atrophicans, panniculitis</p>
<p class="tabh"><i class="calibre3">Rheum</i> (~60%, espec. if not Rx’d): <b class="calibre4">recurrent mono- or oligoarthritis of large joints</b> (classically knee), synovitis</p>
<p class="tab"><i class="calibre3">Neurologic</i> (rare!)<i class="calibre3">:</i> subacute encephalomyelitis, polyneuropathy</p></td>
</tr>
</table>
<p class="tsr">(<i class="calibre3">CID</i> 2006;43:1089; <i class="calibre3">Lancet</i> 2012;379:461; <i class="calibre3">NEJM</i> 2014;370:1724)</p>
<p class="h2a">Diagnostic studies</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">EM present:</i> confirmed in appropriate geographic setting; no need for testing (likely sero ⊖)</p>
<p class="bl"><span class="sbl">•</span> <i class="calibre3">EM absent</i> (ie, stage 2 or 3 disease): 2-step testing</p>
<p class="bl1">1<sup class="calibre15">st</sup> step: ELISA screen (false ⊕ common, false ⊖ w/ early abx or &lt;6 wk after tick bite)</p>
<p class="bl1">2<sup class="calibre15">nd</sup> step: if ⊕ ELISA, confirm with Western blot (↑ Sp)</p>
<p class="bl"><span class="sbl">•</span> ✔ CSF if suspected neuro disease: ⊕ CSF Ab if (IgG<sub class="calibre8">CSF</sub>/IgG<sub class="calibre8">serum</sub>)/(alb<sub class="calibre8">CSF</sub>/alb<sub class="calibre8">serum</sub>) &gt;1</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">NEJM</i> 2014;370:1724; <i class="calibre3">JAMA</i> 2016;315:1767 &amp; 2461)</span></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Prophylaxis:</b> tick avoidance, protective clothing, tick ✔ q24h, DEET</p>
<p class="bl1">Chemoprophylaxis w/ doxycycline 200 mg PO × 1 <i class="calibre3">only</i> if <i class="calibre3">all</i> of the following:</p>
<p class="bl2">1. <i class="calibre3">Ixodes scapularis</i> tick attached ≥36 h</p>
<p class="bl2">2. Local Lyme carriage in ticks ≥20% (peak season in endemic area)</p>
<p class="bl2">3. Abx can be given w/in ≤72 h of tick bite</p>
<p class="bl2">4. No contraindication to doxy (eg, preg, allergy, age &lt;8 y)</p>
<p class="bl1">If criteria 1–4 met, NNT to prevent 1 case ~50; w/o doxy, risk of Lyme after tick bite 1–3%</p>
<p class="bl1">Regardless of Ppx, monitor for fever, flu-like sx, rash (erythema migrans) × 30 d</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Abx</b> (ISDA 2019): <i class="calibre3">if</i> clin. manifest. <i class="calibre3">and</i> ⊕ serology in endemic area (unless isol. EM)</p>
<p class="bl1">Isolated EM: <b class="calibre4">doxy</b> 100 mg PO bid × 10 d (altern: cefurox or amox × 14 d or azithro × 7 d)</p>
<p class="bl1"><i class="calibre3">Arthritis:</i> <b class="calibre4">doxy</b> 100 mg PO bid × 28 d (alternative: cefurox or amox × 28 d)</p>
<p class="bl1"><i class="calibre3">Carditis or meningitis:</i> <b class="calibre4">CTX</b> 2 g IV q24h or doxy 100 mg PO bid (IV vs. PO depends on severity, clinical improvement) × 2–3 wk</p>
<p class="bl"><span class="sbl">•</span> Consider coinfection if severe/refractory sx, persistent fever, cytopenias</p>
<p class="h"><a id="page_6-21" class="calibre7"></a>B<small class="calibre30">ABESIOSIS</small></p>
<p class="h2a">Microbiology &amp; epidemiology</p>
<p class="bl"><span class="sbl">•</span> Infxn w/ parasite <i class="calibre3">Babesia microti</i> (U.S.), transmitted by <i class="calibre3">Ixodes</i> ticks; also a/w transfusion</p>
<p class="bl"><span class="sbl">•</span> Europe &amp; U.S. (more commonly MN, WI, <b class="calibre4">coastal areas &amp; islands of MA</b>, NY, NJ, RI, CT)</p>
<p class="bl"><span class="sbl">•</span> Peak incidence June–August <span class="s1r">(<i class="calibre3">MMWR</i> 2012;61:505)</span></p>
<p class="h2a">Clinical manifestations <span class="s">(typically 1–4 wk after tick exposure;</span> &lt;<span class="s">9 wk if transfusion)</span></p>
<p class="bl"><span class="sbl">•</span> Range from asx to fevers, sweats, myalgias, &amp; HA to severe hemolytic anemia, hemoglobinuria, &amp; death (degree of parasitemia correlates roughly with severity)</p>
<p class="bl"><span class="sbl">•</span> Risk factors for severe disease: <b class="calibre4">asplenia</b>, ↓ cellular immunity, TNF inhib, ↑ age, pregnancy</p>
<p class="h2a">Diagnosis <span class="s">(<i class="calibre3">NEJM</i> 2012;366:2397)</span></p>
<p class="bl"><span class="sbl">•</span> Clinical syndrome <b class="calibre4">+ blood smear w/ intraerythrocytic parasites</b></p>
<p class="bl"><span class="sbl">•</span> Repeat smears (q12–24h) if sx persist despite negative initial smear</p>
<p class="bl"><span class="sbl">•</span> PCR serum if smear ⊖ and high clinical suspicion, serum IgG can help but some false ⊕</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">JAMA</i> 2016;315:1767)</span></p>
<p class="bl"><span class="sbl">•</span> Atovaquone &amp; azithro for mild/mod illness; <b class="calibre4">call ID if severe</b> (azithro/atovaquone/clinda)</p>
<p class="bl"><span class="sbl">•</span> Duration depends on host; immunosupp Pts often need longer Rx</p>
<p class="bl"><span class="sbl">•</span> Exchange transfusion if parasitemia &gt;10%, severe hemolysis or SIRS</p>
<p class="h">E<small class="calibre30">HRLICHIOSIS</small>/A<small class="calibre30">NAPLASMOSIS</small></p>
<p class="h2a">Microbiology</p>
<p class="bl"><span class="sbl">•</span> Gram ⊖ obligate intracellular bacterium; <b class="calibre4">human monocytic ehrlichiosis</b> (<i class="calibre3">E. chaffeensis</i>, HME); <b class="calibre4">human granulocytic anaplasmosis</b> (<i class="calibre3">A. phagocytophilum</i>, HGA)</p>
<p class="bl"><span class="sbl">•</span> Transmission: HME by <i class="calibre3">Amblyomma americanum</i>, <i class="calibre3">Dermacentor variabilis;</i> HGA by <i class="calibre3">Ixodes</i></p>
<p class="h2a">Epidemiology</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">HGA</b> cases typically in New Engl, mid-Atl, MN; <b class="calibre4">HME</b> in SE and south-central U.S.</p>
<p class="bl"><span class="sbl">•</span> Peak incidence spring and early summer; can be transmitted by blood transfusion</p>
<p class="h2a">Clinical manifestations <span class="s">(typically w/in 3 wk of tick exposure)</span></p>
<p class="bl"><span class="sbl">•</span> Asx or nonspecific: fever, myalgias, malaise, HA, cough, dyspnea; onset often acute</p>
<p class="bl"><span class="sbl">•</span> Laboratory: leukopenia, thrombocytopenia, ↑ aminotransferases, LDH, Aφ, renal insuff</p>
<p class="bl"><span class="sbl">•</span> More severe disease can occur with bacterial superinfection in HGA</p>
<p class="h2a">Diagnosis</p>
<p class="bl"><span class="sbl">•</span> Acute: intraleukocytic morulae on peripheral blood smear (rare); <b class="calibre4">PCR;</b> later: serology</p>
<p class="h2a">Treatment <span class="s">(<i class="calibre3">JAMA</i> 2016;315:1767)</span></p>
<p class="bl"><span class="sbl">•</span> Start Rx based on clinical suspicion; definitive dx requires PCR (may not detect all spp.)</p>
<p class="bl"><span class="sbl">•</span> Doxycycline 100 mg PO bid (often × 10 d); should defervesce in ≤48 h, else reconsider dx</p>
<p class="h">R<small class="calibre30">OCKY</small> M<small class="calibre30">OUNTAIN</small> S<small class="calibre30">POTTED</small> F<small class="calibre30">EVER</small> (RMSF)</p>
<p class="h2a">Microbiology &amp; epidemiology</p>
<p class="bl"><span class="sbl">•</span> Infection with <i class="calibre3">Rickettsia rickettsii</i> (Gram ⊖ obligate intracellular bacterium)</p>
<p class="bl"><span class="sbl">•</span> Transmitted by <i class="calibre3">Dermacentor variabilis, D. andersoni</i> (dog tick); peak in spring/early summer</p>
<p class="bl"><span class="sbl">•</span> Occurs in <b class="calibre4">mid-Atl, SE, Midwest</b>, New Engl, NW, Canada, Mexico, Central &amp; S. America</p>
<p class="bl"><span class="sbl">•</span> Consider other rickettsial spp.: <i class="calibre3">R. akari</i> (Rickettsial pox), <i class="calibre3">R. conorii</i> (Mediterranean spotted fever), <i class="calibre3">R. africae</i> (African tick bite fever), <i class="calibre3">R. felis</i> (Flea rickettsiosis)</p>
<p class="h2a">Clinical manifestations <span class="s">(typically w/in 1 wk of tick exposure)</span></p>
<p class="bl"><span class="sbl">•</span> Nonspecific: <b class="calibre4">fever</b>, <b class="calibre4">HA</b>, ΔMS, myalgias, N/V, occasionally abdominal pain</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rash</b> (2–5 d <i class="calibre3">after</i> onset) = <i class="calibre3">centripetal:</i> starts on ankles and wrists → trunk, palms, &amp; soles; progresses from macular to maculopapular to petechial</p>
<p class="bl"><span class="sbl">•</span> Severe cases → vasculitis, hypoperfusion/shock, end-organ damage; more likely in elderly</p>
<p class="bl"><span class="sbl">•</span> Up to 75% mortality if untreated, 5–10% even w/ Rx (esp. if delayed) <span class="s1r">(<i class="calibre3">NEJM</i> 2005;353:551)</span></p>
<p class="h2a">Diagnosis</p>
<p class="bl"><span class="sbl">•</span> Usually a clinical dx; <i class="calibre3">requires early clinical suspicion</i> given risks of delayed Rx</p>
<p class="bl"><span class="sbl">•</span> Acute illness dx by <b class="calibre4">skin bx</b> for rickettsiae (Se ~70%); 7–10 d after sx onset, serology ⊕</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> Doxycycline 100 mg PO bid <i class="calibre3">(give empirically if clinical suspicion)</i></p>
<p class="h">T<small class="calibre30">ULAREMIA</small></p>
<p class="h2a">Microbiology</p>
<p class="bl"><span class="sbl">•</span> Infxn w/ <i class="calibre3">Francisella tularensis</i> via contact w/ animal tissue, aerosol, tick/insect bite</p>
<p class="h2a">Clinical manifestations <span class="s">(typically w/in 2–10 d of exposure)</span></p>
<p class="bl"><span class="sbl">•</span> Acute onset of fever, HA, nausea; ulcer w/ black eschar at site of entry; LAN; PNA</p>
<p class="h2a">Diagnosis &amp; treatment</p>
<p class="bl"><span class="sbl">•</span> Hazardous and difficult to Cx, alert lab. Serology ⊕ by wk 2. PCR by research lab.</p>
<p class="bl"><span class="sbl">•</span> Streptomycin or gentamicin × 7–14 d; empiric Rx may be needed given challenges in dx</p>
<h2 class="ct"><a id="h92" class="calibre7"></a><a id="page_6-22" class="calibre7"></a><a href="part0002.html#rh101" class="calibre7">FEVER SYNDROMES</a></h2>
<p class="cst"><i class="calibre3">Temperature</i> ≥100.4°F or ≥<i class="calibre3">38°C</i></p>
<p class="h2a">Diagnostic approach</p>
<p class="bl"><span class="sbl">•</span> Thorough history including ROS, PMH/PSH, immunizations, including from childhood</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Fever curve</b> (holding antipyretics); less likely to mount fever if: chronic renal or liver disease, extremes of age, protein calorie malnutrition, immunosuppression, steroid use</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Exposures:</b> travel, occupation or hobbies, animals and insects, sexual contacts, TB; consider age, geography, season and incubation time in relation to exposures</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Physical exam:</b> complete exam w/ focus on mucous membranes &amp; conjunctiva; cardiac murmurs; liver and spleen size; skin, genitals, lymph nodes, &amp; joints; complete neuro exam incl cranial nerves and meningeal signs</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">If rash:</b> location, duration, progression/Δ in appearance, was prodrome present</p>
<p class="h">F<small class="calibre30">EVER</small> <small class="calibre30">OF</small> U<small class="calibre30">NKNOWN</small> O<small class="calibre30">RIGIN</small> (FUO)</p>
<p class="h2a">Definition &amp; etiologies</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Fever</b> (as per above def) on &gt;1 occasion during ≥3 wk &amp; <b class="calibre4">no dx</b> despite 1 wk of evaluation</p>
<p class="bl"><span class="sbl">•</span> More likely to be <i class="calibre3">unusual manifestation of common disease</i> than an uncommon disease</p>
<p class="bl"><span class="sbl">•</span> In Pts with HIV: &gt;75% causes are infectious, but <i class="calibre3">rarely due to HIV itself</i></p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Frequent reassessment needed</b> to identify focal signs and progression of disease</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Category</b></p></td>
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Etiologies of Classic FUO</b> <span class="tfont1">(<i class="calibre3">Archives</i> 2003;163:545; <i class="calibre3">Medicine</i> 2007;86:26)</span></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Infection ~30%</b></p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">Tuberculosis:</b> disseminated or extrapulm disease can have normal CXR, PPD, sputum AFB; bx (lung, liver, bone marrow) for granulomas has 80–90% yield in miliary disease</p>
<p class="tabh"><b class="calibre4">Abscess:</b> dental, paraspinal, hepatic, splenic, subphrenic, pancreatic, perinephric, pelvic, prostatic abscess or prostatitis, appendicitis</p>
<p class="tab"><b class="calibre4">Endocarditis:</b> consider HACEK orgs, <i class="calibre3">Bartonella</i>, <i class="calibre3">Legionella</i>, <i class="calibre3">Coxiella</i></p>
<p class="tab">Osteomyelitis, sinusitis, Lyme, typhoid, 1° CMV or EBV, malaria<sup class="calibre35">,</sup> <i class="calibre3">Babesia</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Connective tissue disease ~30%</b></p></td>
<td class="bg0-b"><p class="tabh"><b class="calibre4">Giant cell arteritis/PMR:</b> headache, scalp pain, jaw claudication, visual disturbances, myalgias, arthralgias, ↑ ESR</p>
<p class="tab"><b class="calibre4">Adult-onset Still’s:</b> evanescent truncal rash, LAN, pharyngitis, ↑↑ ferritin</p>
<p class="tab"><b class="calibre4">PAN</b>, <b class="calibre4">ANCA</b> ⊕, <b class="calibre4">other vascul.;</b> SLE, RA, psoriatic or reactive arthritis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab"><b class="calibre4">Neoplasm ~20%</b></p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Lymphoma:</b> LAN, HSM, ↓ Hct or plt, ↑ LDH; leukemia, myelodysplasia</p>
<p class="tab"><b class="calibre4">Renal cell carcinoma:</b> microscopic hematuria, ↑ Hct</p>
<p class="tab"><b class="calibre4">HCC</b>, <b class="calibre4">pancreatic and colon cancers</b>, <b class="calibre4">sarcomas, mastocytosis</b></p>
<p class="tab">Atrial myxomas: obstruction, embolism, constitutional symptoms</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab"><b class="calibre4">Misc ~20%</b></p></td>
<td class="bg"><p class="tab">Drugs, factitious, DVT/PE, hematoma</p>
<p class="tab">Thyroiditis or thyroid storm, adrenal insufficiency, pheochromocytoma</p>
<p class="tab">Granulomatous hepatitis (many causes), <b class="calibre4">sarcoidosis</b>, Kikuchi’s, Behçet’s</p>
<p class="tabh">Familial Mediterranean fever (peritonitis, episodic fever, pleuritis; ↑ WBC &amp; ESR during attacks); other defects in innate immunity</p></td>
</tr>
</table>
<p class="h2a">Workup</p>
<p class="bl"><span class="sbl">•</span> Focus by H&amp;P, incl: CBC w/ diff, lytes, BUN, Cr, LFTs, ESR, CRP, ANA, RF, cryoglobulin, LDH, CK, SPEP, 3 sets BCx (off of abx), U/A, UCx, PPD or IGRA, HIV Ab ± PCR, heterophile Ab (EBV serologies if ), CMV antigen, Hep serologies if LFTs abnl</p>
<p class="bl"><span class="sbl">•</span> Stop unnecessary meds (only 20% with a med cause have eos or rash), reassess 1–3 wk</p>
<p class="bl"><span class="sbl">•</span> Imaging: CXR, chest &amp; abd CT, consider tagged WBC, gallium scan, PET, TTE, LENI</p>
<p class="bl"><span class="sbl">•</span> Consider temporal artery bx if ↑ ESR and age &gt;60, particularly if other s/s</p>
<p class="bl"><span class="sbl">•</span> Consider BM aspirate &amp; bx (esp. if signs of marrow infiltration) or liver bx (esp. if ↑ Aϕ): even w/o localizing s/s, yield may be up to 24% (path and cx) <span class="s1r">(<i class="calibre3">Archives</i> 2009;169:2018)</span></p>
<p class="bl"><span class="sbl">•</span> Pursue abnormalities raised by above w/u (eg, bx, MRI, etc., for dx, <i class="calibre3">not</i> screening)</p>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> Empiric abx <b class="calibre4"><i class="calibre3">not</i></b> indicated (unless Pt neutropenic)</p>
<p class="bl"><span class="sbl">•</span> Empiric glucocorticoids not indicated unless strong suspicion for specific rheumatologic dx</p>
<p class="bl"><span class="sbl">•</span> Up to 30% of cases remain undiagnosed, most spontaneously defervesce (wks to mos)</p>
<p class="h">F<small class="calibre30">EVER</small> <small class="calibre30">AND</small> R<small class="calibre30">ASH</small></p>
<p class="h2a">Approach to diagnostic workup</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Meningococcemia, endocarditis, RMSF, sepsis, toxic shock need urgent dx &amp; Rx</b></p>
<p class="bl"><span class="sbl">•</span> Workup: CBC w/ diff, lytes, BUN/Cr, LFTs, LDH, CK, U/A, HIV Ab ± PCR, BCx (off abx)</p>
<p class="bl"><span class="sbl">•</span> To narrow Ddx: characterize time course of rash, progression &amp; morphology</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Erythema multiforme:</b> symmetric “target” lesions often of palms, soles, &amp; mucous memb</p>
<p class="bl1">Infxn etiol: HSV 1/2, <i class="calibre3">Mycoplasma</i>, syphilis, tick-borne diseases, etc.</p>
<p class="bl1">Non-infxn etiol: meds (eg, NSAIDs, sulfa), malignancy, autoimmune &amp; rheum disease</p>
<p class="bl"><a id="page_6-23" class="calibre1"></a><span class="sbl">•</span> <b class="calibre4">Erythema nodosum:</b> tender erythematous or violaceous nodules usually symmetric on LE</p>
<p class="bl1">Infxn etiol: Strep, TB, EBV, <i class="calibre3">Bartonella</i>, HBV, psittacosis, fungal, <i class="calibre3">L. venereum</i>, etc.</p>
<p class="bl1">Non-infxn etiol: sarcoidosis, IBD, Behçet’s, other rheum, pregnancy/OCP use</p>
<p class="bl"><span class="sbl">•</span> Pursue specific dx based on exposure hx &amp; exam, including serologies, viral swab PCR, antigen tests and possibly skin biopsy ± exam of vesicular or bullae fluid if present</p>
<p class="bl"><span class="sbl">•</span> Etiologies more broad in immunosupp. Pts, dx testing should be earlier and more extensive; higher risk of critical illness due to disseminated or rapidly progressive infxns</p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre27"/>
<col class="calibre28"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Variable</b></p></td>
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Possible Etiology</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Summer/fall &gt; other seasons</p></td>
<td class="bg0-b"><p class="tab">Enterovirus</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Winter</p></td>
<td class="bg0-b"><p class="tab">Parvovirus, Meningococcemia</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Spring/summer</p></td>
<td class="bg0-b"><p class="tab">Measles/rubella, Lyme, RMSF</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Year-round</p></td>
<td class="bg0-b"><p class="tab">Adenovirus, <i class="calibre3">Mycoplasma</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Cat and dog exposure</p></td>
<td class="bg0-b"><p class="tab"><i class="calibre3">Bartonella, Pasteurella, Toxoplasma, Capnocytophaga</i></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Tick exposure</p></td>
<td class="bg0-b"><p class="tab">Lyme, RMSF, Ehrlichiosis, Anaplasmosis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Adult &lt;30 y</p></td>
<td class="bg0-b"><p class="tab">Mononucleosis (EBV or CMV)</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Inadequate immunization</p></td>
<td class="bg0-b"><p class="tab">Measles, Rubella, VZV, influenza</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Sexually active</p></td>
<td class="bg0-b"><p class="tab">HIV, syphilis, disseminated gonococcal infection, HSV2</p></td>
</tr>
<tr class="calibre12">
<td class="bg" colspan="2"><p class="tab"><b class="calibre4">Consider noninfectious causes:</b> allergy/DRESS, DVT, phlebitis, vasculitides, neutrophilic dermatoses, gout, connective tissues dis., malignancy, foreign body rxn</p></td>
</tr>
</table>
<p class="h2a">Treatment</p>
<p class="bl"><span class="sbl">•</span> Empiric abx <i class="calibre3">not</i> indicated (unless Pt neutropenic or critically ill)</p>
<p class="bl"><span class="sbl">•</span> Consider important empiric isolation precautions (ie, varicella → airborne/contact; measles → airborne; meningococcus → droplet) while workup pending</p>
<p class="h">F<small class="calibre30">EVER</small> <small class="calibre30">IN</small> <small class="calibre30">A</small> R<small class="calibre30">ETURNED</small> T<small class="calibre30">RAVELER</small></p>
<table class="t-topbot1">
<colgroup class="calibre9">
<col class="calibre29"/>
<col class="calibre44"/>
</colgroup>
<tr class="calibre12">
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Region or Exposure</b></p></td>
<td class="bg1-b"><p class="tabhead"><b class="calibre4">Common Etiologies</b></p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Sub-Saharan Africa</p></td>
<td class="bg0-b"><p class="tab"><b class="calibre4">Malaria</b> &gt;&gt; dengue, rickettsial disease, enteric disease</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Southeast Asia</p></td>
<td class="bg0-b"><p class="tab">Dengue &gt; malaria, enteric disease (<i class="calibre3">S. typhi</i>), Chikungunya</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Central &amp; S. America</p></td>
<td class="bg0-b"><p class="tab">Enteric disease, malaria, dengue, Zika</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Caribbean &amp; Mexico</p></td>
<td class="bg0-b"><p class="tab">Dengue &gt;&gt; Chikungunya &gt; malaria. Also consider Zika.</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Middle East</p></td>
<td class="bg0-b"><p class="tab">Middle East Respiratory Syndrome</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Freshwater swimming</p></td>
<td class="bg0-b"><p class="tab">Schistosomiasis, leptospirosis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Unpurified drinking water</p></td>
<td class="bg0-b"><p class="tabh">Enteric disease (<i class="calibre3">E. coli</i> &gt;&gt; <i class="calibre3">S. typhi</i>, <i class="calibre3">Campylobacter</i>, hepatitis E &gt; <i class="calibre3">Vibrio cholerae</i>), amebic liver abscess</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Lacking immunizations</p></td>
<td class="bg0-b"><p class="tab">HAV/HBV, <i class="calibre3">S. typhi</i>, influenza, measles, rubella, yellow fever</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">Animal bite</p></td>
<td class="bg0-b"><p class="tab">Rabies</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-br"><p class="tab">African “safari”</p></td>
<td class="bg0-b"><p class="tab">Rickettsial disease, African trypanosomiasis</p></td>
</tr>
<tr class="calibre12">
<td class="bg0-r"><p class="tab">Adult &lt;30 years</p></td>
<td class="bg"><p class="tab">Mononucleosis (EBV or CMV)</p></td>
</tr>
</table>
<p class="tsr">(<i class="calibre3">NEJM</i> 2017;376:548)</p>
<p class="bl"><span class="sbl">•</span> Pts visiting friends and relatives abroad are most likely to contract illness during travel</p>
<p class="bl"><span class="sbl">•</span> Emerging pathogens: Influenza occurs year-round in the tropics. Chikungunya and dengue w/ ↑ areas of transmission, hemorrhagic fevers primarily in Central Africa.</p>
<p class="bl"><span class="sbl">•</span> Consider domestic infxns, STIs, &amp; non-infxn causes. Enteric parasites rarely cause fever.</p>
<p class="h2a">Select clinical manifestations</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Ebola:</b> fever in traveler from area with active transmission of Ebola w/in 21 d: isolate &amp; contact state health department (<a href="http://www.cdc.gov/vhf/ebola" class="calibre1">http://www.cdc.gov/vhf/ebola</a>)</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Malaria:</b> nonspecific symptoms including diarrhea, myalgias, cough, altered mental status</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Dengue:</b> nonspecific symptoms including headache, severe myalgias, rash/petechiae</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Chikungunya:</b> nonspecific symptoms including joint pain, moderate myalgias, fever</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Typhoid</b> <span class="s1r">(<i class="calibre3">Lancet</i> 2015;385:1136)</span>: constipation, abd pain, possible rash, relative bradycardia</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Rickettsial disease:</b> headache, myalgias, lymphadenopathy, possible rash/eschar</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Zika:</b> fever, rash, arthralgia, H/A, conjunctivitis (<a href="http://www.cdc.gov.zika" class="calibre1">http://www.cdc.gov.zika</a>)</p>
<p class="h2a">Workup</p>
<p class="bl"><span class="sbl">•</span> Routine testing: CBC w/ diff, lytes, LFTs, BCx, UA, rapid malaria test</p>
<p class="bl"><span class="sbl">•</span> <b class="calibre4">Fever in a traveler from a malaria zone is malaria until proven otherwise; consider a medical emergency</b> → <b class="calibre4">hospitalization &amp; empiric Rx.</b> One ⊖ smear does <i class="calibre3">not</i> r/o.</p>
<p class="bl"><span class="sbl">•</span> Other tests based on s/s, labs, exposure, incubation period, geography and seasonality. O&amp;P exam, CXR, blood smears for filaria/Babesiosis/<i class="calibre3">Borrelia</i>, serologies, STI &amp; HIV, PPD or IGRA, bone marrow aspirate, bx of lymph nodes or skin lesions, CSF studies.</p>
<h2 class="ct"><a id="page_6-24" class="calibre7"></a>NOTES</h2>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../k34gmbu8.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-74951b69f9a94472af57c47504abb1f1">Title Page</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-74951b69f9a94472af57c47504abb1f1">Copyright Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-74951b69f9a94472af57c47504abb1f1">Contents</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-74951b69f9a94472af57c47504abb1f1">Contributing Authors</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-74951b69f9a94472af57c47504abb1f1">Foreword</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-74951b69f9a94472af57c47504abb1f1">Preface</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-74951b69f9a94472af57c47504abb1f1">Cardiology</a>
      <ul>
        <li>
          <a href="part0006.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0006.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0006.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0006.html#h4">Coronary Angiography and Revascularization</a>
        </li>
        <li>
          <a href="part0006.html#h5">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h6">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0006.html#h7">Heart Failure</a>
        </li>
        <li>
          <a href="part0006.html#h8">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0006.html#h9">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0006.html#h10">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0006.html#h11">Hypertension</a>
        </li>
        <li>
          <a href="part0006.html#h12">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0006.html#h13">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0006.html#h14">Arrhythmias</a>
        </li>
        <li>
          <a href="part0006.html#h15">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0006.html#h16">Syncope</a>
        </li>
        <li>
          <a href="part0006.html#h17">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0006.html#h18">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0006.html#h19">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0007.html#6LJU0-74951b69f9a94472af57c47504abb1f1">Pulmonary</a>
      <ul>
        <li>
          <a href="part0007.html#h20">Dyspnea</a>
        </li>
        <li>
          <a href="part0007.html#h21">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0007.html#h22">Asthma</a>
        </li>
        <li>
          <a href="part0007.html#h23">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0007.html#h24">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0007.html#h25">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0007.html#h26">Hemoptysis</a>
        </li>
        <li>
          <a href="part0007.html#h27">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0007.html#h28">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0007.html#h29">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0007.html#h30">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0007.html#h31">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0007.html#h32">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h33">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0007.html#h34">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0007.html#h35">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0007.html#h36">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0007.html#h37">Toxicology</a>
        </li>
        <li>
          <a href="part0007.html#h38">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-74951b69f9a94472af57c47504abb1f1">Gastroenterology</a>
      <ul>
        <li>
          <a href="part0008.html#h39">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0008.html#h40">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0008.html#h41">Diarrhea</a>
        </li>
        <li>
          <a href="part0008.html#h42">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0008.html#h43">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0008.html#h44">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0008.html#h45">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0008.html#h46">Pancreatitis</a>
        </li>
        <li>
          <a href="part0008.html#h47">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0008.html#h48">Hepatitis</a>
        </li>
        <li>
          <a href="part0008.html#h49">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0008.html#h50">Cirrhosis</a>
        </li>
        <li>
          <a href="part0008.html#h51">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0008.html#h52">Ascites</a>
        </li>
        <li>
          <a href="part0008.html#h53">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-74951b69f9a94472af57c47504abb1f1">Nephrology</a>
      <ul>
        <li>
          <a href="part0009.html#h54">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0009.html#h55">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h56">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0009.html#h57">Renal Failure</a>
        </li>
        <li>
          <a href="part0009.html#h58">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h59">Urinalysis</a>
        </li>
        <li>
          <a href="part0009.html#h60">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-74951b69f9a94472af57c47504abb1f1">Hematology-Oncology</a>
      <ul>
        <li>
          <a href="part0010.html#h61">Anemia</a>
        </li>
        <li>
          <a href="part0010.html#h62">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0010.html#h63">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0010.html#h64">Coagulopathies</a>
        </li>
        <li>
          <a href="part0010.html#h65">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0010.html#h66">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0010.html#h67">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0010.html#h68">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0010.html#h69">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0010.html#h70">Leukemia</a>
        </li>
        <li>
          <a href="part0010.html#h71">Lymphoma</a>
        </li>
        <li>
          <a href="part0010.html#h72">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0010.html#h73">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0010.html#h74">Lung Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h75">Breast Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h76">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h77">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0010.html#h78">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0010.html#h79">Hepatocellular Carcinoma (HCC)</a>
        </li>
        <li>
          <a href="part0010.html#h80">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0010.html#h81">Chemotherapy &amp; Immunotherapy Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-74951b69f9a94472af57c47504abb1f1">Infectious Diseases</a>
      <ul>
        <li>
          <a href="part0011.html#h82">Pneumonia</a>
        </li>
        <li>
          <a href="part0011.html#h83">Fungal Infections</a>
        </li>
        <li>
          <a href="part0011.html#h84">Infections in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0011.html#h85">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0011.html#h86">Soft Tissue and Bone Infections</a>
        </li>
        <li>
          <a href="part0011.html#h87">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0011.html#h88">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0011.html#h89">Tuberculosis</a>
        </li>
        <li>
          <a href="part0011.html#h90">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0011.html#h91">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0011.html#h92">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-74951b69f9a94472af57c47504abb1f1">Endocrinology</a>
      <ul>
        <li>
          <a href="part0012.html#h93">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h94">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h95">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h96">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0012.html#h97">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0012.html#h98">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-74951b69f9a94472af57c47504abb1f1">Rheumatology</a>
      <ul>
        <li>
          <a href="part0013.html#h99">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0013.html#h100">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0013.html#h101">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0013.html#h102">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0013.html#h103">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0013.html#h104">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0013.html#h105">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0013.html#h106">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0013.html#h107">Vasculitis</a>
        </li>
        <li>
          <a href="part0013.html#h108">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0013.html#h109">Cryoglobulinemia</a>
        </li>
        <li>
          <a href="part0013.html#h110">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-74951b69f9a94472af57c47504abb1f1">Neurology</a>
      <ul>
        <li>
          <a href="part0014.html#h111">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0014.html#h112">Seizures</a>
        </li>
        <li>
          <a href="part0014.html#h113">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0014.html#h114">Dizziness</a>
        </li>
        <li>
          <a href="part0014.html#h115">Stroke</a>
        </li>
        <li>
          <a href="part0014.html#h116">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0014.html#h117">Headache</a>
        </li>
        <li>
          <a href="part0014.html#h118">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-74951b69f9a94472af57c47504abb1f1">Consults</a>
      <ul>
        <li>
          <a href="part0015.html#h119">Surgical Issues</a>
        </li>
        <li>
          <a href="part0015.html#h120">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0015.html#h121">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-74951b69f9a94472af57c47504abb1f1">Appendix</a>
      <ul>
        <li>
          <a href="part0016.html#h122">ICU Medications &amp; Treatment of Hypotension/Shock</a>
        </li>
        <li>
          <a href="part0016.html#h123">Antibiotics</a>
        </li>
        <li>
          <a href="part0016.html#h124">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-74951b69f9a94472af57c47504abb1f1">Abbreviations</a>
    </li>
    <li>
      <a href="part0018.html#H5A40-74951b69f9a94472af57c47504abb1f1">Index</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-74951b69f9a94472af57c47504abb1f1">Photo Inserts</a>
      <ul>
        <li>
          <a href="part0019.html#h125">Radiology</a>
        </li>
        <li>
          <a href="part0019.html#h126">Echocardiography &amp; Coronary Angiography</a>
        </li>
        <li>
          <a href="part0019.html#h127">Peripheral Blood Smears &amp; Leukemias</a>
        </li>
        <li>
          <a href="part0019.html#h128">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0022.html#KVCC0-74951b69f9a94472af57c47504abb1f1">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0010.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../k34gmbu8.html" class="calibreAHome">start
</a>

    
      <a href="part0012.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
